

59. Nucleotides

Part LI¹⁾

Synthesis and Biological Activities of (2'–5')Adenylate Trimer Conjugates with 2'-Terminal 3'-O-(ω -Hydroxyalkyl) and 3'-O-(ω -Carboxyalkyl) Spacers

by Cornelia Hörndler^{a)}, Robert J. Suhadolnik^{b)}, Nicholas F. Muto^{c)}, Earl E. Henderson^{c)}^{d)},
Ming-Xu Guan^{d)}, and Wolfgang Pfeleiderer^{a)}*

^{a)} Fakultät für Chemie, Universität Konstanz, Postfach 5560, D-78434 Konstanz

^{b)} Department of Biochemistry, ^{c)} Fels Institute for Institute for Cancer Research and Molecular Biology,

^{d)} Department of Microbiology and Immunology, Temple University School of Medicine, Philadelphia, PA 19140, USA

(6.XII.96)

An efficient strategy for the synthesis of (2'–5')adenylate trimer conjugates with 2'-terminal 3'-O-(ω -hydroxyalkyl) and 3'-O-(ω -carboxyalkyl) spacers is reported. Npeoc-protected adenosine building blocks **37**–**40** for phosphoramidite chemistry carrying a 3'-O-[11-(levulinoyloxy)undecyl], 3'-O-{2-[2-(levulinoyloxy)ethoxy]ethyl}, 3'-O-[5-(2-cyanoethoxycarbonyl)pentyl], and 3'-O-{5-[(9H-fluoren-9-ylmethoxy)carbonyl]pentyl} moiety, respectively, were prepared (npeoc = 2-(4-nitrophenyl)ethoxycarbonyl). Condensation with the cordycepin (3'-deoxyadenosine) dimer **1** led to the corresponding trimers **42**, **43**, **47**, and **48**. Whereas the levulinoyl (lev) and 9H-fluoren-9-ylmethyl (fm) blocking groups could be cleaved off selectively from the trimers **42**, **43**, and **48** yielding the intermediates **44**, **45**, and **49** for the synthesis of the 3'-O-(ω -hydroxyalkyl)trimers **53**, **54** and the cholesterol conjugates **59**–**61**, the 2-cyanoethyl (ce) protecting group of **47**, however, could not be removed in a similar manner from the carboxy function. Trimer **47** served as precursor for the preparation of the trimer **55** with a terminal 3'-O-(5-carboxypentyl)adenosine moiety. The metabolically stable 3'-O-alkyl-(2'–5')A derivatives were tested regarding inhibition of HIV-1 syncytia formation and HIV-1 RT activity. Only the conjugate **59** showed significant effects, whereas the trimers **53**–**55** and the conjugates **60** and **61** were less potent inhibitors, even at 100-fold larger concentrations.

1. Introduction. – Despite of the successful isolation of the AIDS-causing human immunodeficiency virus (HIV) by *Montagnier* and coworkers [2] and *Gallo* and coworkers [3] in 1983, up to now no 'cure' for AIDS could be established. All so far approved drugs belong to the 2',3'-dideoxynucleoside class (AZT, DDI, DDC), their target being the retrovirus-specific reverse transcriptase (RT) [4], but serious toxic side effects (*e.g.* bone-marrow suppression) reinforced the search for other anti-HIV drugs [5]. Between HIV production and the level of (2'–5')oligoadenylates ((2'–5')A), mediators in the interferon-induced response to virus infection (2–5A synthetase/RNase L pathway [6][7]), exists an inverse correlation [8]. Therefore, extending the period during which the cellular level of (2'–5')A is high seems a promising strategy for anti-HIV chemotherapy.


¹⁾ Part L: [1].

A metabolically more stable and nevertheless untotoxic derivative of (2'–5')A is the cordycepin (3'-deoxyadenosine) trimer [9], first chemically synthesized by *Charubala* and *Pfleiderer* in 1980 [10]. As expected, it inhibited virus production when encapsuled in liposomes in μM concentration [11]. Surprisingly the target of the cordycepin trimer was found to be the HIV-1 reverse transcriptase (RT) [12]. It is most likely that this inhibitory effect is caused by complexation of the cordycepin trimer with uridine residues in the anticodon domain of tRNA^{Lys,3} [13], the primer of RT, thus weakening the complex formation of RT and its primer. A further 1000-fold augmentation of antiviral activity could be achieved by attaching cholesterol to the 2'- or 5'-end of cordycepin trimers *via* ester linkages [14]. In a previous publication [15], we reported on the synthesis of a new type of (2'–5')adenylate trimer conjugates with 3'-*O*-(2-hydroxyalkyl) spacer. The synthesis was realized by phosphoramidite chemistry using the npe/npeoc blocking group strategy [16–18], (npe = 2-(4-nitrophenyl)ethyl, npeoc = 2-(4-nitrophenyl)ethoxycarbonyl) the crucial point being the selective deprotection of the spacer's OH function from the appropriately blocked trimer in order to enable the coupling of the cholesterol (cholest-5-en-3 β -ol) moiety of the spacer. For protection of the spacer's OH moiety, the acetyl group was used and cleaved off from the fully blocked trimer in 60% yield. We now want to report on a strategy using the levulinoyl group [19][20] to protect 3'-*O*-(ω -hydroxyalkyl) spacers as well as on the synthesis of trimers and a cholesterol conjugate with a 3'-*O*-(5-carboxypentyl) spacer.

2. Syntheses. – Analogously to our previously developed method [15], npeoc-protected adenosine building blocks **37**–**40** served as intermediates, which afforded trimers on condensation with phosphoramidite **1** of a cordycepin dimer [15]. The multistep synthesis of these monomeric building blocks was based on *N*⁶,2'-*O*,5'-*O*-tris(trityl)adenosine (**2**), prepared from adenosine by a known procedure [21–23]. As ω -hydroxyalkyl spacers appropriately protected for the alkylation (11-bromoundecyloxy)dimethyl(thexyl)silane (**3**; thexyl = 1,1,2-trimethylpropyl), (12-bromododecyloxy)dimethyl(thexyl)silane (**4**), and [2-(2-iodoethoxy)ethoxy]dimethyl(thexyl)silane (**6**) were obtained in 78–56% yield starting from the corresponding alcohols, with 2-(2-iodoethoxy)ethanol (**5**) resulting from *Finkelstein* reaction of the chloroprecursor (55% yield). Reaction of spacers **3**, **4**, and **6** with *N*⁶,2'-*O*,5'-*O*-tris(trityl)adenosine (**2**) under *Williamson* conditions using NaH as base afforded the 3'-*O*-alkyl ethers **7**–**9** (90–82%), which led after removal of the silyl groups with fluoride ions to the alcohols **10**–**12** (94–87%).

Furthermore, alkylation of **2** went on more smoothly with ethyl 6-bromohexanoate than with the free acid and yielded ether **13** (71%), which gave on treatment with THF/EtOH/1M NaOH 2:2:1 acid **14** (94%).

For protection of the OH function, levulinic acid (= 4-oxopentanoic acid, levOH) was applied whereas the COOH function was blocked either with the 2-cyanoethyl(cc) or (9*H*-fluoren-9-yl)methyl (fm) group. The protecting groups were introduced in the presence of *N*-[3-(dimethylamino)propyl]-*N'*-ethylcarbodiimide (ECD) and 4-(dimethylamino)pyridine (DMAP) to give the esters **15**–**19** in 92–67% yields. The trityl groups were cleaved off with 80% AcOH/H₂O at 100° yielding the 3'-*O*-alkyladenosines **20**–**24** (88–64%) and paving the way for the introduction of the 2-(4-nitrophenyl)-ethoxycarbonyl (npeoc) groups [16–18]. Transient protection of **20** and **22**–**24** using hexamethyldisilazane and subsequent reaction with 1-methyl-3-[2-(4-nitrophenyl)-




npeoc = 2-(4-nitrophenyl)ethoxycarbonyl, MeOTr = monomethoxytrityl, npe = 2-(4-nitrophenyl)ethyl,
ⁱPr = isopropyl, tds = dimethyl(thexyl)silyl

ethoxycarbonyl]-1*H*-imidazolium chloride afforded, after desilylation with aqueous acetic acid, the *N*⁶-npeoc derivatives **25**–**28** (79–60%). Then the 5'-OH functions were selectively monomethoxytritylated leading to **29**–**32** (89–67%), and the 2'-OH positions blocked using 1-methyl-3-[2-(4-nitrophenyl)ethoxycarbonyl]-1*H*-imidazolium chloride and DMAP to give **33**–**36** (89–91%). Finally, the monomeric building blocks **37**–**40** were obtained in 92–76% yield by detritylation of their precursors **33**–**36**.

By hydrazinolysis, the levulinoyl protecting group of **33** was selectively cleaved off without harming the npeoc groups, and the alcohol **41** was isolated in 94% yield, whereas removal of the acetyl group from the previously reported corresponding 3'-*O*-(2-acetoxyethyl)-5'-*O*-(monomethoxytrityl)-*N*⁶-[2-(4-nitrophenyl)ethoxycarbonyl]-2'-*O*-[2-(4-nitrophenyl)ethoxysulfonyl]adenosine could only be performed in 63% yield [15]. As already mentioned, the trimers **42** (93%) and **43** (94%) were synthesized by condensation of the monomeric building blocks **37** and **38** with the dimeric phosphoramidite **1** in the presence of 1*H*-tetrazole and subsequent I₂ oxidation. Cleavage of the levulinoyl groups led to the alcohols **44** in 94% and **45** in 77% yield, while the acetyl protecting group was only cleaved off in 60% yield from the corresponding trimer [15].

To study the cleavage of the terminal ester functions (COOce or COOfm) to the carboxy group, **36** was treated with piperidine affording under fm deprotection **46** (75%), whereas the removal of ce from **35** using 0.1M 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) occurred only with simultaneous loss of npeoc groups. Consequently, the free acid **49** was synthesized in 87% yield from the fm-blocked trimer **48**, which was obtained, as well as trimer **47**, by coupling of the corresponding building block **39** or **40** with phosphoramidite **1** in 89% (**47**) and 95% (**48**) yield, respectively.

The trimers **44**, **45**, and **47** were stepwise deblocked in good yields first by acid treatment (→ **50** (75%), **51** (76%), and **52** (80%), resp.) and then using DBU to give the 3'-*O*-(*ω*-hydroxyalkyl) trimers **53** and **54** and the 3'-*O*-(5-carboxypentyl) trimer as HDBU⁺ salt **55** in 70, 92, and 92% yield, respectively. All these totally deprotected trimers turned out to be well H₂O-soluble.




	R	R ¹	R ²	R ³		R	R ¹	R ²	R ³
7	Tr	(CH ₂) ₁₁ Otds	Tr	Tr	21	H	(CH ₂) ₁₂ Olev	H	H
8	Tr	(CH ₂) ₁₂ Otds	Tr	Tr	22	H	(CH ₂) ₂ O(CH ₂) ₂ Olev	H	H
9	Tr	(CH ₂) ₂ O(CH ₂) ₂ Otds	Tr	Tr	23	H	(CH ₂) ₅ COOce	H	H
10	Tr	(CH ₂) ₁₁ OH	Tr	Tr	24	H	(CH ₂) ₅ COOfm	H	H
11	Tr	(CH ₂) ₁₂ OH	Tr	Tr	25	H	(CH ₂) ₁₁ Olev	H	npeoc
12	Tr	(CH ₂) ₂ O(CH ₂) ₂ OH	Tr	Tr	26	H	(CH ₂) ₂ O(CH ₂) ₂ Olev	H	npeoc
13	Tr	(CH ₂) ₅ COOEt	Tr	Tr	27	H	(CH ₂) ₅ COOce	H	npeoc
14	Tr	(CH ₂) ₅ COOH	Tr	Tr	28	H	(CH ₂) ₅ COOfm	H	npeoc
15	Tr	(CH ₂) ₁₁ Olev	Tr	Tr	29	MeOTr	(CH ₂) ₁₁ Olev	H	npeoc
16	Tr	(CH ₂) ₁₂ Olev	Tr	Tr	30	MeOTr	(CH ₂) ₂ O(CH ₂) ₂ Olev	H	npeoc
17	Tr	(CH ₂) ₂ O(CH ₂) ₂ Olev	Tr	Tr	31	MeOTr	(CH ₂) ₅ COOce	H	npeoc
18	Tr	(CH ₂) ₅ COOce	Tr	Tr	32	MeOTr	(CH ₂) ₅ COOfm	H	npeoc
19	Tr	(CH ₂) ₅ COOfm	Tr	Tr	33	MeOTr	(CH ₂) ₁₁ Olev	npeoc	npeoc
20	H	(CH ₂) ₁₁ Olev	H	H	34	MeOTr	(CH ₂) ₂ O(CH ₂) ₂ Olev	npeoc	npeoc

	R	R ¹	R ²	R ³
35	MeOTr	(CH ₂) ₅ COOce	npeoc	npeoc
36	MeOTr	(CH ₂) ₅ COOfm	npeoc	npeoc
37	H	(CH ₂) ₁₁ Olev	npeoc	npeoc
38	H	(CH ₂) ₂ O(CH ₂) ₂ Olev	npeoc	npeoc
39	H	(CH ₂) ₅ COOce	npeoc	npeoc
40	H	(CH ₂) ₅ COOfm	npeoc	npeoc
41	MeOTr	(CH ₂) ₁₁ OH	npeoc	npeoc
46	MeOTr	(CH ₂) ₅ COOH	npeoc	npeoc
62	MeOTr	(CH ₂) ₅ COOH	H	npeoc
63	MeOTr	(CH ₂) ₅ COOH	npes	npeoc
64	MeOTr	(CH ₂) ₅ COOchol	npes	npeoc
65	H	(CH ₂) ₅ COOchol	npes	npeoc

Tr = trityl, lev = levulinoyl, 1,4-dioxopentyl, ce = 2-cyanoethyl, fm = (9H-fluoren-9-yl)methyl, npes = 2-(4-nitrophenyl)ethoxysulfonyl, chol = cholest-5-en-3 β -yl

Next, conjugate formation was achieved by coupling of the alcohols **44** and **45** with cholesteryl chloroformate under activation with 1-methyl-1*H*-imidazole and DMAP as well as by condensation of acid **49** with cholesterol in the presence of EDC and DMAP to form the fully protected conjugates **56–58** (76–40%), which gave on standard deblocking with acid and DBU the conjugates **59–61** in 80–42% overall yield.

Another route for the preparation of the cholesterol conjugate **61** started from **31**, which gave in the first step on treatment with 0.1M DMU the acid **62** (72%). After 2'-*O*-protection with the 2-(4-nitrophenyl)ethoxysulfonyl (npes) group [24] [25] leading to **63** (86%), the cholesterol moiety was introduced already into the monomeric building block to yield conjugate **64** (60%). Detritylation afforded **65** (89%), and condensation with phosphoramidite **2** led to trimer **66** (49%). Total deprotection of trimer **66** to conjugate **61** was performed similarly to the deblocking of trimer **58** in 53% yield.



R	R ¹	R ²	R ³	R ⁴	R	R ¹	R ²	R ³	R ⁴		
42	MeOTr	npeoc	npeoc	(CH ₂) ₁₁ Olev	npe	53	H	H	(CH ₂) ₁₁ OH	(HDBU)	
43	MeOTr	npeoc	npeoc	(CH ₂) ₂ O(CH ₂) ₂ Olev	npe	54	H	H	(CH ₂) ₂ O(CH ₂) ₂ OH	(HDBU)	
44	MeOTr	npeoc	npeoc	(CH ₂) ₁₁ OH	npe	55	H	H	(CH ₂) ₂ COO(HDBU)	(HDBU)	
45	MeOTr	npeoc	npeoc	(CH ₂) ₂ O(CH ₂) ₂ OH	npe	56	MeOTr	npeoc	npeoc	(CH ₂) ₁₁ OCOOchol	npe
47	MeOTr	npeoc	npeoc	(CH ₂) ₂ COOce	npe	57	MeOTr	npeoc	npeoc	(CH ₂) ₂ O(CH ₂) ₂ OCOOchol	npe
48	MeOTr	npeoc	npeoc	(CH ₂) ₂ COOfm	npe	58	MeOTr	npeoc	npeoc	(CH ₂) ₂ COOchol	npe
49	MeOTr	npeoc	npeoc	(CH ₂) ₂ COOH	npe	59	H	H	(CH ₂) ₁₁ OCOOchol	(HDBU)	
50	H	npeoc	npeoc	(CH ₂) ₁₁ OH	npe	60	H	H	(CH ₂) ₂ O(CH ₂) ₂ OCOOchol	(HDBU)	
51	H	npeoc	npeoc	(CH ₂) ₂ O(CH ₂) ₂ OH	npe	61	H	H	(CH ₂) ₂ COOchol	(HDBU)	
52	H	npeoc	npeoc	(CH ₂) ₂ COOce	npe	66	MeOTr	npeoc	npeoc	(CH ₂) ₂ COOchol	npe

It has also to be mentioned that conjugate **60** with a diethyleneglycol spacer could be dissolved in H₂O and trimer **61** with a pentyl spacer in various buffers, whereas, however, conjugate **59** with a undecyl spacer was only soluble in DMSO and ternary mixtures of CH₂Cl₂/MeOH/H₂O.

3. Biochemical Application. – The 3'-O-(ω -hydroxyalkyl) trimers **53** and **54** and the 3'-O-(ω -carboxyalkyl) trimer **55** as well as the corresponding cholesterol conjugates **59**–**61** were screened by the infected-centers assay to measure their ability to inhibit HIV-1-induced syncytia formation, an indicator of HIV-1 replication in T-cells. The most potent inhibitor of this series of HIV-1 replication is **59**; at 1.6 μ M, this (2'-5')A derivative inhibited HIV-1 syncytia formation 3.4-fold (*Table*). This compares with a decreased inhibition of syncytia by compounds **53**–**55**, **60**, **61**, and 3'-deoxyadenylyl-(2'-5')-3'-deoxyadenylyl-(2'-5')-3'-O-(β -hydroxyethyl)adenosine [15] shown in the *Table* at concentrations of 300 μ M. The inhibition of HIV-1 replication by **59** may be attributed to the 11 % inhibition of HIV-1 reverse transcriptase (RT) and/or pleiotropic activities, since, *e.g.*, alkyl derivatives of glycerol have shown inhibition of HIV-1 replication at the budding stage. With the other 3'-O-alkyl-(2'-5')A derivatives, there is little inhibition of syncytia formation and little inhibition of HIV-1 RT activity. Either these (2'-5')A derivatives are not taken up by HIV-1-infected cells, or, if taken up, they do not induce an inhibitory effect.

Table. Inhibition of HIV-1 Replication by (2'-5') A Trimer Analogs Carrying a Terminal 3'-O-(ω -Substituted Alkyl) Residue

Trimer	Terminal 3'-O-substituent	Inhibition of syncytia formation ^{a)} fold	Inhibition of HIV-1 RT activity ^{b)} [%]
	(CH ₂) ₂ O(CH ₂) ₂ OH	0.9	0
	(CH ₂) ₂ O(CH ₂) ₂ OCOchol	n/a ^{c)}	64
	(CH ₂) ₂ COO(HDBU)	1.3	8
	(CH ₂) ₂ COOchol	n/a ^{c)}	20
	(CH ₂) ₁₁ OH	1.3	1
	(CH ₂) ₁₁ OCOchol	3.4	11
	CH ₂ CH ₂ OH [15]	0.8	0

^{a)} Inhibition of HIV-1 replication was determined by HIV-1-induced syncytia formation (fold reduction). Compound **59** was tested at 1.6 μ M; all the other compounds at 300 μ M. The mean of triplicate determinations is shown; variance did not exceed 5–10%.

^{b)} Percent inhibition of HIV-1 reverse transcriptase (HIV-1 RT) activity was measured under the same conditions as described in Footnote a.

^{c)} Compound exhibited toxicity upon prolonged incubation with Sup T1 cells.

^{d)} Compound **59** was dissolved in 0.5% DMSO.

Experimental Part

General. TLC: Precoated silica gel TLC sheets *F 1500 LS 254* from *Schleicher & Schüll*. Prep. TLC: silica gel *60 PF₂₅₄* (*Merck*). Prep. column flash chromatography (FC): silica gel for flash chromatography (*Baker*); 0.2 bar. HPLC: *Merck-Hitachi L 620*, *L-3000* photo diode array detector; column *RP 18*, *LiChrosphere* 125 \times 4 mm, 5 μ m, *Merck*; flow rate 1 ml/min. UV/VIS: *Perkin-Elmer Lambda 5*; λ_{\max} in nm(log ϵ). ¹H-NMR: *Bruker AC 250*; δ in ppm rel. to CHCl₃ ((D₅)DMSO). ³¹P-NMR: *Jeol JM 6X-400*; δ in ppm rel. to 85% H₃PO₄ soln. light petroleum ether = p.e.

Bioassay. Assays measuring HIV-1-induced syncytia formation were accomplished as described [26].

(*11-Bromoundecyloxy*)dimethyl(1,1,2-trimethylpropyl)silane (**3**). To a soln. of 1*H*-imidazole (7.95 g, 0.12 mol) in abs. THF (100 ml), first dimethyl(1,1,2-trimethylpropyl)silyl chloride (8.4 ml, 43 mmol), and after 10 min, 11-bromoundecanol (9.8 g, 39 mmol) were added. The mixture was stirred overnight, diluted with p.e. (100 ml), and washed with sat. NaCl soln. (3 \times 100 ml). The aq. phases were re-extracted with p.e. (3 \times 50 ml), the combined org. layer dried (Na₂SO₄) and evaporated, and the residue purified by FC (silica gel (100 g), *d* 6.5 cm; p.e. (100 ml), p.e./AcOEt 95:5 (500 ml)): 10.4 g (68%) of **3**. Colourless oil. ¹H-NMR (CDCl₃): 3.55 (t, CH₂O); 3.39 (t, CH₂Br); 1.86 (m, CH₂CH₂Br); 1.60 (m, CH); 1.47–1.28 (m, 8 CH₂); 0.85 (m, 4 MeC); 0.08 (s, 2 MeSi). Anal. calc. for C₁₉H₄₁BrOSi (393.5): C 57.99, H 10.50; found: C 57.95, H 10.34.

(*12-Bromododecyloxy*)dimethyl(1,1,2-trimethylpropyl)silane (**4**). As described for **3**, with 1*H*-imidazole (1.95 g, 29 mmol), THF (40 ml), dimethyl(1,1,2-trimethylpropyl)silyl chloride (1.9 ml, 9.6 mmol), and 12-bromododecanol (2.8 g, 11 mmol). The crude product was distilled (185° 0.4 mbar): 2.2 g (56%) of **4**. Colourless oil. ¹H-NMR (CDCl₃): 3.56 (t, CH₂O); 3.38 (t, CH₂Br); 1.85 (m, CH₂CH₂Br); 1.60 (m, CH); 1.47–1.28 (m, 9 CH₂); 0.85 (m, 4 MeC); 0.09 (s, 2 MeSi). Anal. calc. for C₂₀H₄₃BrOSi (407.6): C 58.94, H 10.63; found: C 58.80, H 10.58.

2-(2-Iodoethoxy)ethanol (**5**). Diethyleneglycol monochlorohydrin (= 2-(2-chloroethoxy)ethanol; 10 ml, 94 mmol) and NaI (1.5 g, 120 mmol) were refluxed in ethyl methyl keton (40 ml) for 1 d. The mixture was diluted with AcOEt (500 ml) and washed with Na₂S₂O₃ soln. (3 \times 500 ml), the aq. phase re-extracted with AcOEt (3 \times 250 ml), the combined org. layer dried (Na₂SO₄) and evaporated, and the residue submitted to vacuum distillation (64°/0.4 mbar): 11.2 g (55%) of **5**. Yellowish oil. ¹H-NMR (CDCl₃): 3.77–3.72 (m, 2 CH₂); 3.61–3.57 (m, CH₂OH); 3.24 (t, CH₂I); 2.20 (br. s, OH). Anal. calc. for C₄H₉IO₂ (216.0): C 22.24, H 4.20; found: C 21.87, H 4.21.

[2-(2-Iodoethoxy)ethoxy]dimethyl(1,1,2-trimethylpropyl)silane (**6**). As described for **3**, with 1*H*-imidazole (10.2 g, 150 mmol), THF (60 ml), dimethyl(1,1,2-trimethylpropyl)silyl chloride (10.8 ml, 55 mmol), and **5** (10.8 g, 50 mmol). Workup and purification by vacuum distillation (96°/0.4 mbar) yielded 14.0 g (78%) of **6**. Colourless

oil. $^1\text{H-NMR}$ (CDCl_3): 3.78–3.72 (*m*, 2 CH_2); 3.58–3.53 (*m*, CH_2Otds); 3.23 (*t*, CH_2I); 1.68–1.55 (*m*, CH); 0.85 (*m*, 4 MeC); 0.09 (*s*, 2 MeSi). Anal. calc. for $\text{C}_{12}\text{H}_{27}\text{IO}_2\text{Si}$ (358.3): C 40.22, H 7.59; found: C 40.38, H 7.55.

3'-O-[11-[Dimethyl(1,1,2-trimethylpropyl)silyloxy]undecyl]-N⁶,2'-O,5'-O-tris(triphenylmethyl)adenosine (7). A mixture of *N*⁶,2'-O,5'-O-tris(triphenylmethyl)adenosine (**2**) [21–23] (7.3 g, 73 mmol) and 80% oil-immersed NaH (0.85 g, 28 mmol) in abs. MeCN (160 ml) was stirred at r.t. for 10 min, then NaI (0.66 g, 4.4 mmol) and **3** (8.7 g, 22 mmol) were added. The mixture was kept overnight, then diluted with AcOEt (100 ml), and washed with phosphate buffer pH (3 × 200 ml). Then the aq. phases were re-extracted with AcOEt (3 × 100 ml). The combined org. layer was dried (Na_2SO_4) and evaporated and the residue purified by FC (silica gel (300 g), 7 × 18 cm; p.e. (250 ml), p.e./AcOEt 9:1 (500 ml), 7:1 (400 ml), 5:1 (600 ml), 3:1 (400 ml), and 2:1 (600 ml)); 8.4 g (88%) of **7**. Colourless foam. TLC (toluene/AcOEt 4:1): *R*_f 0.82. UV (MeOH): 274(4.32). $^1\text{H-NMR}$ (CDCl_3): 7.67, 7.66 (2s, H–(2), H–C(8)); 7.38–7.00 (*m*, 45 H of Tr); 6.9 (*s*, NH); 6.00 (*d*, *J* = 7.1, H–C(1')); 5.13 (*dd*, H–C(2')); 4.10 (*m*, H–C(4')); 3.56 (*t*, CH_2Otds); 3.25–2.85 (*m*, $\text{CH}_2\text{O}-\text{C}(3')$, 2 H–C(5'), H–C(3')); 1.60–1.26 (*m*, CH, 9 CH_2); 0.90–0.80 (*m*, 4 MeC); 0.06, 0.05 (2s, 2 MeSi , diast.). Anal. calc. for $\text{C}_{86}\text{H}_{95}\text{N}_5\text{O}_5\text{Si}$ (1306.8): C 79.04, H 7.33, N 5.36; found: C 78.69, H 7.45, N 5.19.

3'-O-[12-[Dimethyl(1,1,2-trimethylpropyl)silyloxy]dodecyl]-N⁶,2'-O,5'-O-tris(triphenylmethyl)adenosine (8). As described for **7**, with **2** [21–23] (99 mg, 0.1 mmol), 80% oil-immersed NaH (35 mg, 1.2 mmol), abs. MeCN (5 ml), NaI (5 mg, 33 μmol) and **4** (120 mg, 0.3 mmol). Workup and purification by FC (silica gel (5 g), 1.5 × 8 cm; p.e. (50 ml), p.e./AcOEt 9:1 (50 ml), 5:1 (60 ml)) yielded 110 mg (82%) of **8**. Colourless foam. TLC (toluene/AcOEt 4:1): *R*_f 0.77. UV (CH_2Cl_2): 282(sh, 4.17), 274(4.33), 269(sh, 4.32). $^1\text{H-NMR}$ (CDCl_3): 7.67, 7.66 (2s, H–C(2), H–C(8)); 7.38–7.00 (*m*, 45 H of Tr); 6.89 (*s*, NH); 6.00 (*d*, *J* = 7.1, H–C(1')); 5.13 (*dd*, H–C(2')); 4.08 (*m*, H–C(4')); 3.54 (*t*, CH_2Otds); 3.30–2.85 (*m*, $\text{CH}_2\text{O}-\text{C}(3')$, 2 H–C(5'), H–C(3')); 1.65–1.25 (*m*, CH, H_2O , 10 CH_2); 0.85 (*m*, 4 MeC); 0.06, 0.05 (2s, MeSi , diast.). Anal. calc. for $\text{C}_{87}\text{H}_{97}\text{N}_5\text{O}_5\text{Si} \cdot \text{H}_2\text{O}$ (1338.8): C 78.04, H 7.45, N 5.23; found: C 77.64, H 7.53, N 5.13.

3'-O-[2-{2-[Dimethyl(1,1,2-trimethylpropyl)silyloxy]ethoxy}ethyl]-N⁶,2'-O,5'-O-tris(triphenylmethyl)adenosine (9). As described for **7**, with **2** [21–23] (13.3 g, 13 mmol), 80% oil-immersed NaH (2.4 g, 80 mmol), abs. MeCN (150 ml), and **6** (13.3 g, 37 mmol). After 4 h stirring at r.t., workup and purification by FC (silica gel (300 g), 7 × 16 cm; p.e. (500 ml), p.e./AcOEt 9:1 (500 ml), 7:1 (400 ml), 5:1 (300 ml), 3:1 (800 ml), 2:1 (600 ml), 1:1 (500 ml)) gave 14.3 g (90%) of **9**. Colourless foam. TLC (toluene/AcOEt 4:1): *R*_f 0.76. UV (MeOH): 282(sh, 4.24), 274(4.35). $^1\text{H-NMR}$ (CDCl_3): 7.71, 7.68 (2s, H–C(2), H–C(8)); 7.38–7.00 (*m*, 45 H of Tr); 6.91 (*s*, NH); 6.07 (*d*, *J* = 7.4, H–C(1')); 5.15 (*dd*, H–C(2')); 4.11 (*m*, H–C(4')); 3.68–3.50 (*m*, 3 CH_2); 3.33–3.00 (*m*, $\text{CH}_2\text{O}-\text{C}(3')$, 2 H–C(5')); 2.78 (*d*, H–C(3')); 1.58 (*m*, CH); 0.88–0.80 (*m*, 4 MeC); 0.07, 0.06 (2s, MeSi , diast.). Anal. calc. for $\text{C}_{79}\text{H}_{81}\text{N}_5\text{O}_6\text{Si}$ (1224.6): C 77.48, H 6.67, N 5.71; found: C 77.18, H 6.79, N 5.76.

3'-O-(11-Hydroxyundecyl)-N⁶,2'-O,5'-O-tris(triphenylmethyl)adenosine (10). A mixture of **7** (8.4 g, 6.5 mmol), $\text{Bu}_4\text{NF} \cdot 3 \text{H}_2\text{O}$ (2.9 g, 9.2 mmol), and abs. THF (10 ml) was kept at r.t. overnight. Then it was diluted with AcOEt (100 ml) and washed with sat. NaCl soln. (3 × 100 ml). The aq. phases were re-extracted with AcOEt (3 × 100 ml). The combined org. layer was dried (Na_2SO_4) and evaporated and the residue purified by FC (silica gel (150 g), 5.5 × 12 cm; toluene (200 ml), toluene/AcOEt 9:1 (200 ml), 7:1 (160 ml), 6:1 (140 ml), 5:1 (360 ml), 4:1 (400 ml)); 7.1 g (94%) of **10**. Colourless foam. TLC (toluene/AcOEt 4:1): *R*_f 0.24. UV (MeOH): 273(4.32). $^1\text{H-NMR}$ ($(\text{D}_6)\text{DMSO}$): 8.36 (br. *s*, NH); 7.46, 7.45 (2s, H–C(2), H–C(8)); 7.37–6.99 (*m*, 45 H of Tr); 6.10 (*d*, *J* = 7.5, H–C(1')); 5.12 (*dd*, H–C(2')); 4.31 (*t*, OH); 3.92 (*m*, H–C(4')); 3.35 (*m*, CH_2OH); 3.20–2.70 (*m*, $\text{CH}_2\text{O}-\text{C}(3')$, 2 H–C(5')); 2.43 (*d*, H–C(3')); 1.42–1.20 (*m*, 9 CH_2). Anal. calc. for $\text{C}_{79}\text{H}_{79}\text{N}_5\text{O}_5$ (1164.5): C 80.45, H 6.66, N 6.01; found: C 79.88, H 6.66, N 5.86.

3'-O-(12-Hydroxydodecyl)-N⁶,2'-O,5'-O-tris(triphenylmethyl)adenosine (11). As described for **10**, with **8** (1.3 g, 0.9 mmol), $\text{Bu}_4\text{NF} \cdot 3 \text{H}_2\text{O}$ (430 mg, 1.4 mmol), and abs. THF (3 ml). After workup and purification by FC (silica gel (20 g), 3 × 9 cm; toluene (50 ml), toluene/AcOEt 9:1 (100 ml), 6:1 (70 ml), 3:1 (80 ml)), 970 mg (87%) of **11** were obtained. Colourless foam. TLC (toluene/AcOEt 4:1): *R*_f 0.30. UV (MeOH): 282(sh, 4.20), 273(4.34), 268(sh, 4.33). $^1\text{H-NMR}$ ($(\text{D}_6)\text{DMSO}$): 8.35 (br. *s*, NH); 7.48, 7.47 (2s, H–C(2), H–C(8)); 7.37–6.99 (*m*, 45 H of Tr); 6.12 (*d*, *J* = 7.5, H–C(1')); 5.12 (*dd*, H–C(2')); 4.32 (*t*, OH); 3.90 (*m*, H–C(4')); 3.35 (*m*, CH_2OH); 3.20–2.20 (*m*, $\text{CH}_2\text{O}-\text{C}(3')$, 2 H–C(5')); 2.45 (*d*, H–C(3')); 1.40–1.21 (*m*, 10 CH_2). Anal. calc. for $\text{C}_{80}\text{H}_{81}\text{N}_5\text{O}_5$ (1178.5): C 80.51, H 6.76, N 5.94; found: C 80.30, H 6.85, N 5.94.

3'-O-[2-(2-Hydroxyethoxy)ethyl]-N⁶,2'-O,5'-O-tris(triphenylmethyl)adenosine (12). As described for **10**, with **9** (14.3 g, 12 mmol), $\text{Bu}_4\text{NF} \cdot 3 \text{H}_2\text{O}$ (5.0 g, 16 mmol), and abs. THF (30 ml). Workup and purification by FC (silica gel (200 g), 5.5 × 17 cm; CH_2Cl_2 (500 ml), $\text{CH}_2\text{Cl}_2/\text{MeOH}$ 99:1 (500 ml), 98:2 (500 ml), 97:3 (500 ml), 96:4 (500 ml), 95:5 (1500 ml)) gave 12.0 g (91%) of **12**. Colourless foam. TLC ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ 95:5): *R*_f 0.46. UV (MeOH): 282(sh, 4.23), 274(4.25), 270(sh, 4.33). $^1\text{H-NMR}$ ($(\text{D}_6)\text{DMSO}$): 8.37 (br. *s*, NH); 7.49, 7.46 (2s,

H–C(2), H–C(8)); 7.37–7.02 (*m*, 45 H of Tr); 6.13 (*d*, *J* = 7.6, H–C(1')); 5.12 (*dd*, H–C(2')); 4.56 (*t*, OH); 4.03 (*m*, H–C(4')); 3.52–3.40 (*m*, 3 CH₂O); 3.36 (*s*, H₂O); 3.32–2.88 (*m*, CH₂O–C(3'), 2 H–C(5')); 2.45 (*d*, H–C(3')). Anal. calc. for C₇₁H₆₃N₅O₆ · H₂O (1100.3): C 77.50, H 5.95, N 6.36; found: C 77.62, H 6.00, N 6.73.

3'-O-[5-(Ethoxycarbonyl)pentyl]-N⁶,2'-O,5'-O-tris(triphenylmethyl)adenosine (**13**). A mixture of **2** [21–23] (0.23 g, 0.23 mmol) and 80% oil-immersed NaH (40 mg, 1.3 mmol) in abs. MeCN (5 ml) was stirred at r.t. for 10 min, then a catal. amount of NaI and ethyl 6-bromohexanoate (*Fluka*; 0.12 ml, 0.67 mmol) were added. The mixture was kept overnight, then diluted with AcOEt (50 ml), and washed with 10% citric acid soln. (50 ml) and phosphate buffer pH 7 (3 × 50 ml). The aq. phases were re-extracted with AcOEt (3 × 100 ml). The combined org. layer was dried (Na₂SO₄) and evaporated and the residue purified by FC (silica gel (7 g), 2 × 8 cm; p.e. (50 ml), p.e./AcOEt 9:1 (50 ml), 7:1 (40 ml), 5:1 (60 ml), 4:1 (50 ml), 3:1 (80 ml), and 2:1 (30 ml)): 0.19 g (71%) of **13**. Colourless foam, which crystallized from EtOH/H₂O 5:1. Colourless crystals. M.p. 115°. TLC (p.e./AcOEt 3:1): R_f 0.32. UV (MeOH): 282 (sh, 4.23), 274 (4.29). ¹H-NMR ((D₆)DMSO): 8.37 (*s*, NH); 7.47 (2*s*, H–C(2), H–C(8)); 7.38–7.00 (*m*, 45 H of Tr); 6.12 (*d*, *J* = 7.5, H–C(1')); 5.18 (*dd*, H–C(2')); 4.07–3.99 (*q*, CH₂OCO); 3.94 (*m*, H–C(4')); 3.34–3.15, 2.90–2.70 (*m*, CH₂O–C(3'), 2 H–C(5')); 2.43 (*d*, H–C(3')); 2.22 (*t*, CH₂COO); 1.53–1.30 (*m*, 3 CH₂); 1.16 (*t*, Me). Anal. calc. for C₇₅H₆₉N₅O₆ · 0.5 H₂O (1145.3): C 78.65, H 6.16, N 6.11; found: C 78.56, H 6.00, N 6.25.

3'-O-(5-Carboxypentyl)-N⁶,2'-O,5'-O-tris(triphenylmethyl)adenosine (**14**). In THF/EtOH/1*M* NaOH 2:2:1 (100 ml), **13** (6.4 g, 5.6 mmol) was kept at r.t. for 4 h. Then the mixture was neutralized with AcOH, diluted with CHCl₃ (250 ml), and washed with sat. NaCl soln. (3 × 250 ml). The aq. phases were re-extracted with CHCl₃ (3 × 100 ml). The combined org. layer was dried (Na₂SO₄) and evaporated and the residue purified by FC (silica gel (130 g), 5 × 20 cm; CH₂Cl₂ (250 ml), CH₂Cl₂/MeOH 98:2 (200 ml), 95:5 (200 ml), 93:7 (400 ml), 9:1 (300 ml)): 5.8 g (94%) of **14**. Colourless foam. TLC (CH₂Cl₂/MeOH 95:5): R_f 0.34. UV (MeOH): 274 (4.33). ¹H-NMR ((D₆)DMSO): 12.01 (*br. s*, COOH); 8.37 (*s*, NH); 7.48, 7.47 (2*s*, H–C(2), H–C(8)); 7.35–7.00 (*m*, 45 H of Tr); 6.12 (*d*, *J* = 7.0, H–C(1')); 5.18 (*dd*, H–C(2')); 3.95 (*m*, H–C(4')); 3.20–3.10, 2.95–2.65 (2*m*, CH₂O–C(3'), 2 H–C(5')); 2.45 (*d*, H–C(3')); 2.15 (*t*, CH₂COO); 1.52–1.12 (*m*, 3 CH₂). Anal. calc. for C₇₃H₆₅N₅O₆ (1108.6): C 79.11, H 5.91, N 6.32; found: C 79.19, H 5.97, N 6.61.

3'-O-{11-[(1,4-Dioxopentyl)oxy]undecyl}-N⁶,2'-O,5'-O-tris(triphenylmethyl)adenosine (**15**). After stirring a soln. of **10** (7.1 g, 6.1 mmol), EDC · HCl (1.4 g, 7.4 mmol), and DMAP (1.1 g, 9.0 mmol) in abs. CH₂Cl₂ (40 ml) for 5 min at r.t., levulinic acid (1.2 g, 9.9 mmol) was added. The soln. was stirred for 3 h, then diluted with CHCl₃ (100 ml) and washed with sat. NaCl soln. (3 × 100 ml). The aq. phases were re-extracted with CHCl₃ (3 × 100 ml). The combined org. layer was dried (Na₂SO₄) and evaporated and the residue purified by FC (silica gel (160 g), 5.5 × 13 cm; toluene (200 ml), toluene/AcOEt 9:1 (200 ml), 7:1 (160 ml), 5:1 (720 ml)): 6.6 g (86%) of **15**. Colourless foam. TLC (toluene/AcOEt 4:1): R_f 0.51. UV (MeOH): 273 (4.31). ¹H-NMR (CDCl₃): 7.68, 7.67 (2*s*, H–C(2), H–C(8)); 7.38–6.99 (*m*, 45 H of Tr); 6.90 (*s*, NH); 6.02 (*d*, *J* = 7.1, H–C(1')); 5.15 (*dd*, H–C(2')); 4.04–4.02 (*m*, H–C(4'), CH₂Olev); 3.28–2.85 (*m*, CH₂O–C(3'), 2 H–C(5'), H–C(3')); 2.72 (*t*, CH₂COO); 2.56 (*t*, CH₂CO); 2.17 (*s*, Me); 1.62–1.26 (*m*, 9 CH₂). Anal. calc. for C₈₃H₈₃N₅O₇ (1262.6): C 78.96, H 6.63, N 6.66; found: C 78.45, H 6.68, N 5.45.

3'-O-{12-[(1,4-Dioxopentyl)oxy]dodecyl}-N⁶,2'-O,5'-O-tris(triphenylmethyl)adenosine (**16**). As described for **15**, with **11** (680 mg, 580 μmol), EDC · HCl (130 mg, 720 μmol), DMAP (100 mg, 860 μmol), abs. CH₂Cl₂ (10 ml), and levulinic acid (135 mg, 810 μmol). Workup and purification by FC (silica gel (15 g), 2.5 × 10 cm; toluene (100 ml), toluene/AcOEt 9:1 (100 ml)) led to 550 mg (74%) of **16**. Colourless foam. TLC (toluene/AcOEt 4:1): R_f 0.52. UV (MeOH): 283 (sh, 4.16), 274 (4.32), 268 (sh, 4.31). ¹H-NMR (CDCl₃): 7.68, 7.67 (2*s*, H–C(2), H–C(8)); 7.38–7.00 (*m*, 45 H of Tr); 6.89 (*s*, NH); 6.01 (*d*, *J* = 7.1, H–C(1')); 5.13 (*dd*, H–C(2')); 4.07–4.01 (*m*, H–C(4'), CH₂Olev); 3.20, 3.05, 2.85 (3*m*, CH₂O–C(3'), 2 H–C(5'), H–C(3')); 2.73 (*t*, CH₂COO); 2.57 (*t*, CH₂CO); 2.17 (*s*, Me); 1.60–1.25 (*m*, 10 CH₂). Anal. calc. for C₈₄H₈₅N₅O₇ · 0.5 H₂O (1285.6): C 78.48, H 6.74, N 5.45; found: C 78.34, H 6.84, N 5.48.

3'-O-{2-[2-[(1,4-Dioxopentyl)oxy]ethoxy]ethyl}-N⁶,2'-O,5'-O-tris(triphenylmethyl)adenosine (**17**). As described for **15**, with **12** (11.4 g, 10 mmol), EDC · HCl (2.4 g, 12 mmol), DMAP (1.8 g, 14 mmol), abs. CH₂Cl₂ (60 ml), and levulinic acid (2.45 g, 21 mmol). Workup and purification by FC (silica gel (250 g), 5.5 × 23 cm, toluene/AcOEt 1:1 (1000 ml)) led to 11.0 g (92%) of **17**. Colourless foam. TLC (CH₂Cl₂/MeOH 95:5): R_f 0.78. UV (MeOH): 279 (sh, 4.32), 274 (4.35). ¹H-NMR (CDCl₃): 7.73, 7.67 (2*s*, H–C(2), H–C(8)); 7.36–6.99 (*m*, 45 H of Tr); 6.95 (*s*, NH); 6.05 (*d*, *J* = 7.3, H–C(1')); 5.04 (*dd*, H–C(2')); 4.12–4.08 (*m*, H–C(4'), CH₂Olev); 3.66–3.54 (*m*, 2 CH₂O); 3.32–3.00 (*m*, CH₂O–C(3'), 2 H–C(5')); 2.78 (*d*, H–C(3')); 2.63 (*t*, CH₂COO); 2.48 (*t*, CH₂CO); 2.09 (*s*, Me); 1.82 (*s*, H₂O). Anal. calc. for C₇₆H₆₉N₅O₈ · 0.5 H₂O (1189.4): C 76.75, H 5.93, N 5.88; found: C 76.57, H 5.83, N 5.98.

3'-O-[5-(2-Cyanoethoxycarbonyl)pentyl]-N⁶,2'-O,5'-O-tris(triphenylmethyl)adenosine (**18**). As described for **15**, with **14** (8.3 g, 7.1 mmol), EDC · HCl (1.6 g, 8.5 mmol), DMAP (1.2 g, 9.9 mmol), abs. CH₂Cl₂ (20 ml), and 2-cyano-

ethanol (1.0 ml, 15.0 mmol). Workup and purification by FC (silica gel (200 g), 2 × 20 cm; CH₂Cl₂ (750 ml), CH₂Cl₂/MeOH 99:1 (500 ml), 98:2 (500 ml), 97:3 (500 ml), 96:4 (500 ml)) gave 7.4 g (90%) of **18**. Colourless foam. TLC (toluene/AcOEt 4:1): *R_f* 0.45. TLC (CH₂Cl₂/MeOH 95:5): *R_f* 0.73. UV (MeOH): 282 (sh, 4.34), 274 (4.35), 277 (sh, 4.19). ¹H-NMR (CDCl₃): 7.68, 7.67 (2s, H-C(2), H-C(8)); 7.37–7.00 (m, 45 H of Tr); 6.89 (s, NH); 6.01 (d, *J* = 7.2, H-C(1')); 5.11 (dd, H-C(2')); 4.25 (t, CH₂OCO); 4.07 (m, H-C(4')); 3.27–2.79 (m, CH₂O-C(3'), 2 H-C(5'), H-C(3')); 2.60 (t, CH₂CN); 2.32 (t, CH₂COO); 1.68–1.32 (m, H₂O, 3 CH₂). Anal. calc. for C₇₆H₆₈N₆O₆ · 0.5 H₂O (1170.4): C 77.99, H 5.94, N 7.18; found: C 77.65, H 6.04, N 7.18.

3'-O-{5-[(9H-Fluoren-9-ylmethoxy)carbonyl]pentyl}-N⁶,2'-O,5'-O-tris(triphenylmethyl)adenosine (**19**). As described for **15**, with **14** (190 mg, 170 μmol), EDC · HCl (39 mg, 200 μmol), DMAP (30 mg, 250 μmol), abs. CH₂Cl₂ (5 ml), and (9H-fluoren-9-yl)methanol (90 mg, 460 μmol). Workup and purification by FC (silica gel (10 g, 1.5 × 13 cm; p.e. (50 ml), p.e./AcOEt 9:1 (50 ml), 7:1 (40 ml), 5:1 (120 ml), 3:1 (80 ml), and 2:1 (60 ml)) led to 150 mg (67%) of **19**. Colourless foam. TLC (toluene/AcOEt 4:1): *R_f* 0.58. UV (CH₂Cl₂): 300 (3.83), 285 (sh, 4.28), 272 (sh, 4.57), 266 (4.61). ¹H-NMR ((D₆)DMSO): 8.35 (s, NH); 7.85–8.62 (2d, 4 H of fm); 7.46, 7.45 (2s, H-C(2), H-C(8)); 7.42–6.98 (m, 4 H of fm, 45 H of Tr); 6.03 (d, *J* = 7.2, H-C(1')); 5.16 (dd, H-C(2')); 4.42 (d, CH₂O of fm); 4.24 (t, H-C(9) of fm); 3.92 (m, H-C(4')); 3.30–2.65 (m, CH₂O-C(3'), 2 H-C(5')); 2.45 (d, H-C(3')); 2.21 (t, CH₂COO); 1.45–1.14 (m, 3 CH₂). Anal. calc. for C₈₇H₇₅N₅O₆ (1286.6): C 81.22, H 5.88, N 5.44; found: C 80.90, H 5.87, N 5.47.

3'-O-{11-[(1,4-Dioxopentyl)oxy]undecyl}adenosine (**20**). A soln. of **15** (6.1 g, 4.9 mmol) in 80% AcOH/H₂O (30 ml) was kept at 100° for 90 min, then evaporated, co-evaporated with H₂O (3 × 5 ml) and MeOH (3 × 5 ml), and purified by FC (silica gel (100 g), 5 × 13 cm; CH₂Cl₂ (200 ml), CH₂Cl₂/MeOH 95:5 (200 ml), 9:1 (600 ml)): 2.2 g (86%) of **20**. The resulting foam crystallized from EtOH/H₂O 1:1. Colourless crystals. M.p. 137°. TLC (CHCl₃/MeOH 9:1): *R_f* 0.38. UV (MeOH): 259 (4.17). ¹H-NMR ((D₆)DMSO): 8.32, 8.11 (2s, H-C(2), H-C(8)); 7.30 (s, NH₂); 5.85 (d, *J* = 6.2, H-C(1')); 5.42–5.39 (m, OH-C(2'), O-H(5')); (dd, H-C(2')); 4.05–3.80 (m, H-C(3'), H-C(4'), CH₂Olev); 3.71–3.43 (m, CH₂O-C(3'), 2 H-C(5')); 2.67 (t, CH₂CO); 2.40 (t, CH₂CO); 2.09 (s, Me); 1.52–1.25 (m, 9 CH₂). Anal. calc. for C₂₆H₄₁N₅O₇ (535.6): C 58.30, H 7.72, N 13.07; found: C 58.16, H 7.69, N 12.73.

3'-O-{12-[(1,4-Dioxopentyl)oxy]dodecyl}adenosine (**21**). As described for **20**, with **16** (0.55 g, 0.43 mmol) and 80% AcOH/H₂O (5 ml). FC (silica gel (15 g), 2.5 × 10 cm; CH₂Cl₂ (50 ml), CH₂Cl₂/MeOH 95:5 (100 ml), 9:1 (100 ml)) gave a foam which was crystallized from EtOH/H₂O 1:1 (2 ml): 0.16 g (67%) of **21**. Colourless crystals. M.p. 138°. TLC (CHCl₃/MeOH 9:1): *R_f* 0.46. UV (MeOH): 259 (4.17). ¹H-NMR ((D₆)DMSO): 8.34, 8.11 (2s, H-C(2), H-C(8)); 7.34 (s, NH₂); 5.85 (d, *J* = 6.3, H-C(1')); 5.41–5.38 (m, OH-C(2'), OH-C(5')); 4.72 (dd, H-C(2')); 4.05–3.93 (m, H-C(3'), H-C(4'), CH₂Olev); 3.65–3.45 (m, CH₂O-C(3'), 2 H-C(5')); 2.65 (t, CH₂COO); 2.43 (t, CH₂CO); 2.08 (s, Me); 1.52–1.24 (m, 10 CH₂). Anal. calc. for C₂₇H₄₃N₅O₇ (549.8): C 58.99, H 7.88, N 12.74; found: C 59.00, H 7.70, N 12.83.

3'-O-{2-[(1,4-Dioxopentyl)oxy]ethoxy}ethyladenosine (**22**). As described for **20**, with **17** (11.0 g, 9.2 mmol) and 80% AcOH/H₂O (50 ml). FC (silica gel (200 g), 5.5 × 19 cm; CH₂Cl₂ (500 ml), CH₂Cl₂/MeOH 95:5 (500 ml), 9:1 (1500 ml), 4:1 (300 ml)) yielded 3.7 g (88%) of **22**. Colourless foam. TLC (CHCl₃/MeOH 9:1): *R_f* 0.50. UV (MeOH): 258 (4.17). ¹H-NMR ((D₆)DMSO): 8.33, 8.12 (2s, H-C(2), H-C(8)); 7.35 (s, NH₂); 5.86 (d, *J* = 6.3, H-C(1')); 5.42 (m, OH-C(5')); 5.39 (d, OH-C(2')); 4.73 (dd, H-C(2')); 4.12–3.98 (m, H-C(3'), H-C(4'), CH₂Olev); 3.84–3.55 (m, 2 CH₂O, CH₂O-C(3'), 2 H-C(5')); 2.68 (t, CH₂COO); 2.45 (t, CH₂CO); 2.08 (s, Me). Anal. calc. for C₁₉H₂₇N₅O₈ (453.6): C 50.33, H 6.00, N 15.44; found: C 50.09, H 6.03, N 15.06.

3'-O-[5-(2-Cyanoethoxycarbonyl)pentyl]adenosine (**23**). As described for **20**, with **18** (170 mg, 0.15 mmol) and 80% AcOH/H₂O (5 ml). Purification by FC (silica gel (5 g), 1 × 16 cm; CH₂Cl₂ (50 ml), CH₂Cl₂/MeOH 98:2 (50 ml), 96:4 (100 ml), 92:8 (50 ml)) gave 41 mg (64%) of **23**. Colourless foam. TLC (CHCl₃/MeOH 9:1): *R_f* 0.41. UV (MeOH): 258 (4.19). ¹H-NMR ((D₆)DMSO): 8.34, 8.12 (2s, H-C(2), H-C(8)); 7.35 (br. s, NH₂); 5.86 (d, *J* = 6.3, H-C(1')); 5.50–5.39 (m, OH-C(5'), OH-C(2')); 4.75 (dd, H-C(2')); 4.22 (m, CH₂OCO); 4.02 (m, H-C(4')); 3.91 (m, H-C(3')); 3.71–3.42 (m, CH₂O-C(3'), 2 H-C(5')); 2.87 (t, CH₂CN); 2.35 (t, CH₂COO); 1.60–1.33 (m, 3 CH₂). Anal. calc. for C₁₉H₂₆N₆O₆ (434.6): C 52.53, H 6.03, N 19.34; found: C 52.31, H 6.15, N 18.88.

3'-O-{5-[(9H-Fluoren-9-ylmethoxy)carbonyl]pentyl}adenosine (**24**). As described for **20**, with **19** (2.9 g, 2.3 mmol) and 80% AcOH/H₂O (20 ml). FC (silica gel (60 g), 4 × 16 cm; CH₂Cl₂ (200 ml), CH₂Cl₂/MeOH 95:5 (200 ml), 9:1 (400 ml)) gave 0.99 g (78%) of **24** as a foam which crystallized from H₂O/EtOH 2:1. Colourless crystals. M.p. 147°. TLC (CHCl₃/MeOH 9:1): *R_f* 0.50. UV (MeOH): 299 (3.77), 288 (3.72), 263 (4.52), 257 (sh, 4.50). ¹H-NMR ((D₆)DMSO): 8.35, 8.12 (2s, H-C(2), H-C(8)); 7.88–7.62, 7.42–7.29 (m, 8 H of fm, NH₂); 5.86 (d, *J* = 6.2, H-C(1')); 5.50–5.41 (m, OH-C(5'), OH-C(2')); 4.75 (dd, H-C(2')); 4.45 (d, CH₂O of fm); 4.28 (t, H-C(9) of fm); 4.02 (m, H-C(4')); 3.91 (m, H-C(3')); 3.70–3.40 (m, CH₂O-C(3'), 2 H-C(5')); 2.30 (t,

CH₂COO); 1.55–1.20 (*m*, 3 CH₂). Anal. calc. for C₃₀H₃₃N₅O₆ (559.6): C 64.39, H 5.94, N 12.51; found: C 63.90, H 5.94, N 12.73.

3'-O-{11-[(1,4-Dioxopentyl)oxy]undecyl}-N⁶-[2-(4-nitrophenyl)ethoxycarbonyl]adenosine (**25**). A mixture of **20** (1.6 g, 3.0 mmol), hexamethyldisilazane (7.5 ml), abs. dioxane (7.5 ml), and a catal. amount of (NH₄)₂SO₄ was refluxed for 3 h and then evaporated. The residue was dissolved in toluene (10 ml) and the soln. filtered and evaporated. Then 1-methyl-3-[2-(4-nitrophenyl)ethoxycarbonyl]-1*H*-imidazolium chloride [16] (1.9 g, 6.0 mmol) and abs. CH₂Cl₂ (30 ml) were added. The mixture was kept overnight, filtered, and the filtrate evaporated. To the residue, 80% AcOH/H₂O (20 ml) was added. The soln. was stirred for 1 h, then evaporated, and co-evaporated with H₂O (3 × 5 ml) and MeOH (3 × 5 ml) and the residue purified by FC (silica gel (50 g), 4 × 20 cm; CH₂Cl₂ (200 ml), CH₂Cl₂/MeOH 99:1 (200 ml), 98:2 (200 ml), 95:5 (200 ml)): 1.7 g (79%) of **25**. Colourless foam. TLC (CHCl₃/MeOH 9:1): *R*_f 0.62. UV (MeOH): 267(4.43). ¹H-NMR ((D₆)DMSO): 10.60 (*s*, NH); 8.67, 8.61 (2*s*, H-C(2), H-C(8)); 8.15 (*d*, 2 H *o* to NO₂); 7.61 (*d*, 2 H *m* to NO₂); 5.97 (*d*, *J* = 5.7, H-C(1')); 5.50 (*m*, OH-C(2')); 5.16 (*t*, OH-C(5')); 4.75 (*dd*, H-C(2')); 4.39 (*t*, CH₂CH₂O of npeoc); 4.05–3.94 (*m*, H-C(3'), H-C(4'), CH₂Olev); 3.70–3.40 (*m*, CH₂O-C(3'), 2 H-C(5')); 3.11 (*t*, CH₂CH₂O of npeoc); 2.67 (*t*, CH₂COO); 2.40 (*t*, CH₂CO); 2.08 (*s*, Me); 1.52–1.24 (*m*, 9 CH₂). Anal. calc. for C₃₅H₄₈N₆O₁₁ (728.8): C 57.68, H 6.64, N 11.53; found: C 57.35, H 6.70, N 11.39.

3'-O-{2-[2-(1,4-Dioxopentyl)oxy]ethoxy}ethyl}-N⁶-[2-(4-nitrophenyl)ethoxycarbonyl]adenosine (**26**). As described for **25**, with **22** (0.51 g, 1.1 mmol), hexamethyldisilazane (3 ml), abs. dioxane (3 ml), a catal. amount of (NH₄)₂SO₄, toluene (10 ml), 1-methyl-3-[2-(4-nitrophenyl)ethoxycarbonyl]-1*H*-imidazolium chloride [16] (0.72 g, 2.3 mmol), abs. CH₂Cl₂ (20 ml), and 80% AcOH/H₂O (5 ml). FC (silica gel (10 g), 2.5 × 7 cm; CH₂Cl₂ (50 ml), CH₂Cl₂/MeOH 99:1 (50 ml), 98:2 (50 ml), 97:3 (50 ml), 96:4 (50 ml)) gave 0.44 g (60%) of **26**. Colourless foam. TLC (CHCl₃/MeOH 95:5): *R*_f 0.28. UV (MeOH): 267(4.45). ¹H-NMR ((D₆)DMSO): (*s*, NH); 8.67, 8.62 (2*s*, H-C(2), H-C(8)); 8.15 (*d*, 2 H *o* to NO₂); 7.50 (*d*, 2 H *m* to NO₂); 5.99 (*d*, *J* = 5.7, H-C(1')); 5.47 (*d*, OH-C(2')); 5.18 (*t*, OH-C(5')); 4.75 (*dd*, H-C(2')); 4.39 (*t*, CH₂CH₂O of npeoc); 4.05–4.13 (*m*, H-C(3'), H-C(4'), CH₂Olev); 3.80–3.58 (*m*, 2 CH₂O, CH₂O-C(3'), 2 H-C(5')); 3.11 (*t*, CH₂CH₂O of npeoc); 2.67 (*t*, CH₂COO); 2.46 (*t*, CH₂CO); 2.07 (*s*, Me). Anal. calc. for C₂₈H₃₄N₆O₁₂ (646.6): C 52.01, H 5.53, N 13.00; found: C 51.80, H 5.43, N 12.62.

3'-O-{5-(2-Cyanoethoxycarbonyl)pentyl}-N⁶-[2-(4-nitrophenyl)ethoxycarbonyl]adenosine (**27**). As described for **25** with **23** (0.40 g, 0.94 mmol), hexamethyldisilazane (2 ml), abs. dioxane (2 ml), a catal. amount of (NH₄)₂SO₄, 1-methyl-3-[4-(4-nitrophenyl)ethoxycarbonyl]-1*H*-imidazolium chloride [16] (0.58 g, 1.9 mmol), abs. CH₂Cl₂ (15 ml), and 80% AcOH/H₂O (5 ml). FC (silica gel (10 g), 2.5 × 8 cm; CH₂Cl₂ (100 ml), CH₂Cl₂/MeOH 99:1 (100 ml), 98:2 (100 ml), 97:3 (50 ml)) led to 0.4 g (70%) of **27**. Colourless foam. TLC (CHCl₃/MeOH 95:5): *R*_f 0.31. UV (MeOH): 267(4.43). ¹H-NMR ((D₆)DMSO): 10.61 (*s*, NH); 8.67, 8.61 (2*s*, H-C(2), H-C(8)); 8.15 (*d*, 2 H *o* to NO₂); 7.50 (*d*, 2 H *m* to NO₂); 5.97 (*d*, *J* = 5.7, H-C(1')); 5.50 (*d*, OH-C(2')); 5.17 (*t*, OH-C(5')); 4.75 (*dd*, H-C(2')); 4.38 (*t*, CH₂CH₂O of npeoc); 4.17 (*t*, CH₂OCO); 4.02 (*m*, H-C(4')); 3.95 (*m*, H-C(3')); 3.68–3.45 (*m*, CH₂O-C(3'), 2 H-C(5')); 3.10 (*t*, CH₂CH₂O of npeoc); 2.86 (*t*, CH₂CN); 2.35 (*t*, CH₂COO); 1.60–1.35 (*m*, 3 CH₂). Anal. calc. for C₂₈H₃₃N₇O₁₀ (627.6): C 53.59, H 5.30, N 15.62; found: C 52.94, H 5.31, N 14.82.

3'-O-{5-(9*H*-Fluoren-9-ylmethoxy)carbonyl}pentyl}-N⁶-[2-(4-nitrophenyl)ethoxycarbonyl]adenosine (**28**). As described for **27**, with **24** (0.64 g, 1.2 mmol), hexamethyldisilazane (6 ml), abs. dioxane (6 ml), a catal. amount of (NH₄)₂SO₄, toluene (10 ml), 1-methyl-3-[4-(4-nitrophenyl)ethoxycarbonyl]-1*H*-imidazolium chloride [16] (0.72 g, 2.3 mmol), abs. CH₂Cl₂ (10 ml), and 80% AcOH/H₂O (10 ml). FC (silica gel (20 g), 3 × 9 cm; CH₂Cl₂ (200 ml), CH₂Cl₂/MeOH 99:1 (200 ml), 98:2 (200 ml)) gave 0.57 g (66%) of **28**. Colourless foam. TLC (CHCl₃/MeOH 95:5): *R*_f 0.35. UV (MeOH): 298(3.84), 286(sh, 3.98), 265(4.52). ¹H-NMR ((D₆)DMSO): 10.62 (*s*, NH); 8.68, 8.62 (2*s*, H-C(2), H-C(8)); 8.17 (*d*, 2 H *o* to NO₂); 7.88 (*d*, 2 H *o* of fm); 7.65–7.55 (*m*, 2 H *o* of fm, 2 H *m* to NO₂); 7.42–7.28 (*m*, 4 H of fm); 5.96 (*d*, *J* = 5.7, H-C(1')); 5.49 (*d*, OH-C(2')); 5.17 (*t*, OH-C(5')); 4.73 (*dd*, H-C(2')); 4.47–4.36 (*m*, CH₂O of fm, CH₂CH₂O of npeoc); 4.25 (*t*, H-C(9) of fm); 4.08 (*m*, H-C(4')); 3.97 (*m*, H-C(3')); 3.70–3.40 (*m*, CH₂O-C(3'), 2 H-C(5')); 3.02 (*t*, CH₂CH₂O of npeoc); 2.21 (*t*, CH₂COO); 1.50–1.15 (*m*, 3 CH₂). Anal. calc. for C₃₉H₄₀N₆O₁₀ (752.8): C 62.23, H 5.36, N 11.16; found: 62.00, H 5.44, N 10.82.

3'-O-{11-[(1,4-Dioxopentyl)oxy]undecyl}-5'-O-{(4-methoxyphenyl)diphenylmethyl}-N⁶-[2-(4-nitrophenyl)ethoxycarbonyl]adenosine (**29**). After co-evaporation with dry pyridine (3 × 5 ml), **25** (1.8 g, 2.5 mmol) and MeOTrCl (1.9 g, 6.2 mmol) were stirred in dry pyridine (20 ml) at r.t. for 1 d. Then the mixture was diluted with AcOEt (100 ml) and washed with sat. NaHCO₃ soln. (3 × 100 ml). The aq. phase was re-extracted with AcOEt (3 × 50 ml), the combined org. layer dried (Na₂SO₄), evaporated, and co-evaporated with toluene (3 × 10 ml), and the crude product purified by FC (silica gel (50 g), 4 × 12 cm; toluene/AcOEt 1:1 (400 ml), toluene/AcOEt/MeOH 50:50:1 (400 ml), 25:25:1 (200 ml)): 1.8 g (74%) of **29**. Colourless foam. TLC (toluene/AcOEt/MeOH 5:4:1): *R*_f

0.58. UV (MeOH): 267(4.51), 233(4.37). ¹H-NMR ((D₆)DMSO): 10.61 (s, NH); 8.57, 8.55 (2s, H-C(2), H-C(8)); 8.16 (d, 2 H *o* to NO₂); 7.60 (d, 2 H *m* to NO₂); 7.34–7.17 (m, 12 H of MeOTr); 6.82 (d, 2 H *o* to MeO); 5.99 (d, *J* = 4.2, H-C(1')); 5.55 (d, OH-C(2')); 4.90 (dd, H-C(2')); 4.38 (t, CH₂CH₂O of npeoc); 4.20 (m, H-C(3')); 4.12 (m, H-C(4')); 3.95 (t, CH₂Olev); 3.33 (s, MeO); 3.65–3.15 (m, CH₂O-C(3'), 2 H-C(5')); 3.09 (t, CH₂CH₂O of npeoc); 2.66 (t, CH₂COO); 2.41 (t, CH₂CO); 2.07 (s, Me); 1.52–1.21 (m, 9 CH₂). Anal. calc. for C₅₅H₆₄N₆O₁₂ (1001.2): C 65.98, H 6.44, N 8.39; found: C 65.49, H 6.43, N 8.26.

3'-O-{2-[2-[(1,4-Dioxopentyl)oxy]ethoxy]ethyl}-5'-O-[(4-methoxyphenyl)diphenylmethyl]-N⁶-[2-(4-nitrophenyl)ethoxycarbonyl]adenosine (**30**). As described for **29**, with **26** (1.65 g, 2.6 mmol), MeOTrCl (0.96 g, 3.1 mmol), and dry pyridine (10 ml). FC (silica gel (35 g), 3 × 14 cm; CH₂Cl₂ (300 ml), CH₂Cl₂/MeOH 99:1 (300 ml), 98:2 (300 ml), 97:3 (150 ml)) gave 1.7 g (73%) of **30**. Colourless foam. TLC (CH₂Cl₂/MeOH 95:5): *R*_f 0.26. UV (MeOH): 267(4.49), 233(4.35). ¹H-NMR ((D₆)DMSO): 10.61 (s, NH); 8.56, 8.54 (2s, H-C(2), H-C(8)); 8.15 (d, 2 H *o* to NO₂); 7.60 (d, 2 H *m* to NO₂); 7.35–7.17 (m, 12 H of MeOTr); 6.82 (d, 2 H *o* to MeO); 6.00 (d, *J* = 4.6, H-C(1')); 5.55 (d, OH-C(2')); 4.94 (dd, H-C(2')); 4.48 (t, CH₂CH₂O of npeoc); 4.25 (m, H-C(3')); 4.15 (m, H-C(4')); 4.05 (t, CH₂Olev); 3.70 (s, MeO); 3.80–3.45 (m, 2 CH₂O, CH₂O-C(3'), 2 H-C(5')); 3.27–3.22 (m, 2 H-C(5')); 3.08 (t, CH₂CH₂O of npeoc); 2.66 (t, CH₂COO); 2.40 (t, CH₂CO); 2.06 (s, Me). Anal. calc. for C₄₈H₅₀N₆O₁₃ (919.0): C 62.74, H 5.48, N 9.15; found: C 62.64, H 5.72, N 9.12.

3'-O-[5-(2-Cyanoethoxycarbonyl)pentyl]-5'-O-[(4-methoxyphenyl)diphenylmethyl]-N⁶-[2-(4-nitrophenyl)ethoxycarbonyl]adenosine (**31**). As described for **29**, with **27** (165 mg, 0.26 mmol), MeOTrCl (160 mg, 0.52 mmol), and dry pyridine (5 ml). FC (silica gel (10 g), 2.5 × 8 cm; CH₂Cl₂ (100 ml), CH₂Cl₂/MeOH 99:1 (100 ml), 98:2 (100 ml)) gave 160 mg (67%) of **31**. Colourless foam. TLC (CH₂Cl₂/MeOH 95:5): *R*_f 0.50. UV (MeOH): 267(4.47), 233(4.32). ¹H-NMR ((D₆)DMSO): 10.62 (s, NH); 8.57, 8.51 (2s, H-C(2), H-C(8)); 8.15 (d, 2 H *o* to NO₂); 7.84 (d, 2 H *m* to NO₂); 7.35–7.17 (m, 12 H of MeOTr); 6.83 (d, 2 H *o* to MeO); 5.99 (d, *J* = 4.4, H-C(1')); 5.55 (d, OH-C(2')); 4.90 (dd, H-C(2')); 4.37 (t, CH₂CH₂O of npeoc); 4.18 (t, CH₂OCO); 4.15–4.10 (m, H-C(4'), H-C(3')); 3.71 (s, MeO); 3.75–3.20 (m, CH₂O-C(3'), 2 H-C(5')); 3.10 (t, CH₂CO of npeoc); 2.88 (t, CH₂CN); 2.31 (t, CH₂COO); 1.55–1.12 (m, 3 CH₂). Anal. calc. for C₄₈H₄₉N₇O₁₁ · H₂O (918.0): C 62.80, H 5.60, N 10.68; found: C 63.02, H 5.56, N 10.45.

3'-O-{5-[1-(9H-Fluoren-9-ylmethoxy)carbonyl]pentyl}-5'-O-[(4-methoxyphenyl)diphenylmethyl]-N⁶-[2-(4-nitrophenyl)ethoxycarbonyl]adenosine (**32**). As described for **29**, with **28** (130 mg, 0.18 mmol), MeOTrCl (65 mg, 0.21 mmol), and dry pyridine (2 ml). The soln. was stirred overnight, then more MeOTrCl (27 mg, 0.09 mmol) was added. After 5 h, the mixture was worked up and the residue purified by FC (silica gel (5 g), 1.5 × 7 cm; CH₂Cl₂ (50 ml), CH₂Cl₂/MeOH 99:1 (50 ml), 98:2 (50 ml)): 160 mg (89%) of **32**. Colourless foam. TLC (CH₂Cl₂/MeOH 95:5): *R*_f 0.52. UV (CH₂Cl₂): 299(4.02), 288 (sh, 4.15), 271 (sh, 4.61), 266(4.68), 232(4.27). ¹H-NMR ((D₆)DMSO): 10.63 (s, NH); 8.59, 8.56 (2s, H-C(2), H-C(8)); 8.15 (d, 2 H *o* to NO₂); 7.85 (d, 2 H of fm); 7.65–7.57 (m, 2 H of fm, 2 H *m* to NO₂); 7.42–7.17 (m, 4 H of fm, 12 H of MeOTr); 6.80 (d, 2 H *o* to MeO); 6.00 (t, 4.3, H-C(1')); 5.58 (d, OH-C(2')); 4.92 (dd, H-C(2')); 4.45–4.35 (m, CH₂O of fm CH₂CH₂O of npeoc); 4.29–4.12 (m, H-C(9) of fm, H-C(4'), H-C(3')); 3.68 (s, MeO); 3.62–3.18 (m, CH₂O-C(3'), 2 H-C(5')); 3.09 (t, CH₂CH₂O of npeoc); 2.23 (t, CH₂COO); 1.50–1.10 (m, 3 CH₂). Anal. calc. for C₅₉H₅₆N₆O₁₁ (1025.1): C 69.13, H 5.51, N 8.20; found: 69.08, H 5.73, N 8.06.

3'-O-{11-[(1,4-Dioxopentyl)oxy]undecyl}-5'-O-[(4-methoxyphenyl)diphenylmethyl]-N⁶,2'-O-bis[2-(4-nitrophenyl)ethoxycarbonyl]adenosine (**33**). A soln. of **29** (79 mg, 79 μmol), DMAP (7 mg, 57 μmol), and 1-methyl-3-[(4-nitrophenyl)ethoxycarbonyl]-1*H*-imidazolium chloride [16] (50 mg, 0.16 mmol) in abs. CH₂Cl₂ (2 ml) was kept at r.t. overnight, then diluted with CHCl₃ (25 ml), and washed with sat. NaCl soln. (3 × 25 ml). The aq. phase was re-extracted with CHCl₃ (3 × 25 ml) and the org. layer dried (Na₂SO₄) and evaporated. Purification by FC (silica gel (4 g), 1.5 × 12 cm; CH₂Cl₂ (25 ml), CH₂Cl₂/MeOH 99:1 (25 ml), 98:2 (50 ml)) gave 84 mg (89%) of **33**. Colourless foam. TLC (CH₂Cl₂/MeOH 95:5): *R*_f 0.63. UV (MeOH): 267(4.56), 234(4.35). ¹H-NMR ((D₆)DMSO): 10.66 (s, NH); 8.60, 8.59 (2s, H-C(2), H-C(8)); 8.15 (d, 2 H *o* to MeO); 6.27 (d, *J* = 2.9, H-C(1')); 5.92 (dd, H-C(2')); 4.70 (t, 4.70 (m, H-C(3'))); 4.35 (t, 2 CH₂CH₂O of npeoc); 4.05 (m, H-C(4')); 3.93 (t, CH₂Olev); 3.70 (s, MeO); 3.40 (m, CH₂O-C(3')); 3.07 (m, 2 H-C(5'), 2 CH₂CH₂O of npeoc); 2.66 (t, CH₂COO); 2.40 (t, CH₂CO); 2.08 (s, Me); 1.53–1.13 (m, 9 CH₂). Anal. calc. for C₆₄H₇₁N₇O₁₆ (1194.3): C 64.36, H 5.99, N 8.21; found: C 63.78, H 6.00, N 8.12.

3'-O-{2-[2-[(1,4-Dioxopentyl)oxy]ethoxy]ethyl}-5'-O-[(4-methoxyphenyl)diphenylmethyl]-N⁶,2'-O-bis[2-(4-nitrophenyl)ethoxycarbonyl]adenosine (**34**). As described for **33**, with **30** (250 mg, 270 μmol), DMAP (16 mg, 130 μmol), 1-methyl-3-[(4-nitrophenyl)ethoxycarbonyl]-1*H*-imidazolium chloride [12] (170 mg, 0.28 mmol), and abs. CH₂Cl₂ (10 ml). After FC (silica gel (10 g), 2.5 × 7 cm; CH₂Cl₂ (100 ml), CH₂Cl₂/MeOH 99:1 (100 ml), 98:2 (100 ml)), 275 mg (91%) of **34** were obtained. Colourless foam. TLC (CH₂Cl₂/MeOH 95:5): *R*_f 0.47. UV (CH₂Cl₂): 266(4.57), 236(4.36). ¹H-NMR ((D₆)DMSO): 10.66 (s, NH); 8.58, 8.57 (2s, H-C(2), H-C(8)); 8.14

(*d*, 4 H *o* to NO₂); 7.65–7.53 (*m*, 4 H *m* to NO₂); 7.30–7.15 (*m*, 12 H of MeOTr); 6.80 (*d*, 2 H *o* to MeO); 6.28 (*d*, *J* = 3.2, H–C(1')); 5.92 (*dd*, H–C(2')); 4.72 (*t*, H–C(3')); 4.40 (*t*, 2 CH₂CH₂O of npeoc); 4.11 (*m*, H–C(4')); 3.98 (*t*, CH₂Olev); 3.70 (*s*, MeO); 3.60–3.40 (*m*, 2 CH₂O, CH₂O–C(3')); 3.31–3.05 (*m*, 2 H–C(5')), 2 CH₂CH₂O of npeoc); 2.75 (*t*, CH₂COO); 2.38 (*t*, CH₂CO); 2.06 (*s*, Me). Anal. calc. for C₅₇H₅₇N₇O₁₇ (1112.1): C 61.56, H 5.17, N 8.82; found: C 61.58, H 5.18, N 8.72.

3'-O-[5-(2-Cyanoethoxycarbonyl)pentyl]-5'-O-[(4-methoxyphenyl)diphenylmethyl]-N⁶,2'-O-bis[2-(4-nitrophenyl)ethoxycarbonyl]adenosine (**35**). As described for **33**, with **31** (110 mg, 120 μmol), DMAP (11 mg, 90 μmol), 1-methyl-3-[(4-nitrophenyl)ethoxycarbonyl]-1*H*-imidazolium chloride [16] (120 mg, 0.37 mmol), and abs. CH₂Cl₂ (5 ml). Purification by FC (silica gel (5 g), 1.5 × 10 cm; toluene/AcOEt 1:1 (100 ml), toluene/AcOEt/MeOH 25:25:1 (50 ml)) gave 110 mg (88%) of **35**. Colourless foam. TLC (CH₂Cl₂/MeOH 95:5): *R*_f 0.68. UV (CH₂Cl₂): 266 (4.60), 237 (4.38). ¹H-NMR ((D₆)DMSO): 10.66 (*s*, NH); 8.59, 8.58 (2*s*, H–C(2), H–C(8)); 8.14 (*d*, 4 H *o* to NO₂); 7.62–7.53 (*m*, 4 H *m* to NO₂); 7.29–7.11 (*m*, 12 H of MeOTr); 6.82 (*d*, 2 H *o* to MeO); 6.27 (*d*, *J* = 2.9, H–C(1')); 5.93 (*dd*, H–C(2')); 4.71 (*t*, H–C(3')); 4.38 (*t*, 2 CH₂CH₂O of npeoc); 4.17 (*t*, CH₂OCO); 4.05 (*m*, H–C(4')); 3.70 (*s*, MeO); 3.75–3.30 (*m*, CH₂O–C(3'), 2 H–C(5')); 3.14–3.08 (*m*, 2 CH₂CH₂O of npeoc); 2.86 (*t*, CH₂CN); 2.24 (*t*, CH₂COO); 1.50–1.15 (*m*, 3 CH₂). Anal. calc. for C₅₇H₅₆N₈O₁₅ (1093.1): C 62.63, H 5.16, N 10.25; found: C 62.04, H 5.31, N 9.77.

3'-O-[5-[(9*H*-Fluoren-9-ylmethoxy)carbonyl]pentyl]-5'-O-[(4-methoxyphenyl)diphenylmethyl]-N⁶,2'-O-bis[2-(4-nitrophenyl)ethoxycarbonyl]adenosine (**36**). As described for **33**, with **32** (76 mg, 74 μmol), DMAP (6 mg, 49 μmol), 1-methyl-3-[(4-nitrophenyl)ethoxycarbonyl]-1*H*-imidazolium chloride [16] (100 mg, 0.32 mmol), and abs. CH₂Cl₂ (1 ml). After FC (silica gel (3 g), 1.5 × 6 cm; CH₂Cl₂ (50 ml), CH₂Cl₂/MeOH 99:1 (50 ml)): 82 mg (91% of **36** were obtained. Colourless foam. TLC (CH₂Cl₂/MeOH 95:5): *R*_f 0.66. UV (CH₂Cl₂): 299 (sh, 4.17), 287 (sh, 4.37), 266 (4.77), 232 (sh, 4.45). ¹H-NMR ((D₆)DMSO): 10.62 (*s*, NH); 8.59, 8.58 (2*s*, H–C(2), H–C(8)); 8.15–8.09 (*m*, 4 H *o* to NO₂); 7.86–7.83 (*m*, 2 H of fm); 7.62–7.40 (*m*, 2 H of fm, 4 H *m* to NO₂); 7.37–7.11 (*m*, 4 H of fm, 12 H of MeOTr); 6.78 (*d*, 2 H *o* to MeO); 6.26 (*d*, *J* = 2.5, H–C(1')); 5.94 (*dd*, H–C(2')); 4.69 (*t*, H–C(3')); 4.39–4.35 (*m*, CH₂O of fm, 2 CH₂O of npeoc); 4.21 (*t*, H–C(9) of fm); 4.03 (*m*, H–C(4')); 3.67 (*s*, MeO); 3.55–3.25 (*m*, CH₂O–C(3'), 2 H–C(5')); 3.12–3.03 (*m*, 2 CH₂CH₂O of npeoc); 2.17 (*t*, CH₂COO); 1.45–1.02 (*m*, 3 CH₂). Anal. calc. for C₆₈H₆₃N₇O₁₅ (1218.3): C 67.04, H 5.21, N 8.05; found: C 66.61, H 5.27, N 8.13.

3'-O-[11-[(1,4-Dioxopentyl)oxy]undecyl]-N⁶,2'-O-bis[2-(4-nitrophenyl)ethoxycarbonyl]adenosine (**37**). A soln. of **33** (350 mg, 0.29 mmol) in MeOH/CHCl₃ 4:1 (5 ml) containing 2% of TsOH was stirred at r.t. for 15 min. The mixture was diluted with CHCl₃ (20 ml) and washed with sat. NaHCO₃ soln. (3 × 20 ml), the aq. phase re-extracted with CHCl₃ (3 × 20 ml), the org. layer dried (Na₂SO₄) and evaporated, and the residue purified by FC (silica gel (10 g), 2.5 × 8 cm; CH₂Cl₂ (100 ml), CH₂Cl₂/MeOH 99:1 (100 ml), 98:2 (100 ml)): 230 mg (85%) of **37**. Colourless foam. TLC (CH₂Cl₂/MeOH 95:5): *R*_f 0.36. UV (MeOH): 266 (4.53). ¹H-NMR ((D₆)DMSO): 10.64 (*s*, NH); 8.66, 8.61 (2*s*, H–C(2), H–C(8)); 8.15 (*m*, 4 H *o* to NO₂); 7.62–7.50 (*m*, 4 H *m* to NO₂); 6.23 (*d*, *J* = 4.6, H–C(1')); 5.67 (*dd*, H–C(2')); 5.25 (*t*, OH–C(5')); 4.41–4.31 (*m*, H–C(3'), 2 CH₂CH₂O of npeoc); 4.04 (*m*, H–C(4')); 3.94 (*t*, CH₂Olev); 3.75–3.30 (*m*, CH₂O–C(3'), 2 H–C(5')); 3.12–3.03 (*m*, 2 CH₂CH₂O of npeoc); 2.70 (*t*, CH₂COO); 2.44 (*t*, CH₂CO); 2.08 (*s*, Me); 1.52–1.19 (*m*, 9 CH₂). Anal. calc. for C₄₄H₅₅N₇O₁₅ (922.0): C 57.32, H 6.01, N 10.63; found: C 57.03, H 5.96, N 10.50.

3'-O-[2-[(1,4-Dioxopentyl)oxy]ethoxy]ethyl]-N⁶,2'-O-bis[2-(4-nitrophenyl)ethoxycarbonyl]adenosine (**38**). As described for **37**, with **34** (120 mg, 0.11 mmol) in MeOH/CHCl₃ 4:1 (1 ml) containing 2% of TsOH. FC (silica gel (3 g), 1.5 × 6 cm; CH₂Cl₂ (25 ml), CH₂Cl₂/MeOH 99:1 (25 ml), 98:2 (25 ml)) gave 77 mg (83%) of **38**. Colourless foam. TLC (CH₂Cl₂/MeOH 95:5): *R*_f 0.38. UV (CH₂Cl₂): 273 (sh, 4.46), 267 (4.50). ¹H-NMR ((D₆)DMSO): 10.66 (*s*, NH); 8.66, 8.61 (2*s*, H–C(2), H–C(8)); 8.15 (*m*, 4 H *o* to NO₂); 7.62–7.50 (*m*, 4 H *m* to NO₂); 6.23 (*d*, 4.7, H–C(1')); 5.68 (*dd*, H–C(2')); 5.29 (*t*, OH–C(5')); 4.42–4.32 (*m*, H–C(3'), CH₂CH₂O of npeoc); 4.09–4.03 (*m*, H–C(4'), CH₂Olev); 3.75–3.42 (*m*, 2 CH₂O, CH₂O–C(3'), 2 H–C(5')); 3.13–3.01 (*m*, 2 CH₂CH₂O of npeoc); 2.65 (*t*, CH₂COO); 2.43 (*t*, CH₂CO); 2.08 (*s*, Me). Anal. calc. for C₃₇H₄₁N₇O₁₆ (839.8): C 52.92, H 4.92, N 11.68; found: C 52.93, H 4.98, N 11.34.

3'-O-[5-(2-Cyanoethoxycarbonyl)pentyl]-N⁶,2'-O-bis[2-(4-nitrophenyl)ethoxycarbonyl]adenosine (**39**). As described for **37**, with **35** (110 mg, 0.10 mmol) and MeOH/CHCl₃ 4:1 (2 ml) containing 2% of TsOH. FC (silica gel (5 g), 1.5 × 7 cm; CH₂Cl₂ (50 ml), CH₂Cl₂/MeOH 99:1 (50 ml), 98:2 (50 ml), 97:3 (50 ml)) gave 64 mg (76%) of **39**. Colourless foam. TLC (CH₂Cl₂/MeOH 95:5): *R*_f 0.60. UV (MeOH): 267 (4.55). ¹H-NMR ((D₆)DMSO): 10.64 (*s*, NH); 8.66, 8.62 (2*s*, H–C(2), H–C(8)); 8.15 (*m*, 4 H *o* to NO₂); 7.62–7.58 (*m*, 4 H *m* to NO₂); 6.22 (*d*, *J* = 4.6, H–C(1')); 5.73 (*dd*, H–C(2')); 5.25 (*t*, OH–C(5')); 4.40–4.31 (*m*, H–C(3'), 2 CH₂CH₂O of npeoc); 4.17 (*t*, CH₂OCO); 4.05 (*m*, H–C(4')); 3.75–3.38 (*m*, CH₂O–C(3'), 2 H–C(5')); 3.12–3.03 (*m*, 2 CH₂CH₂O of npeoc); 2.86 (*t*, CH₂CN); 2.30 (*t*, CH₂COO); 1.56–1.21 (*m*, 3 CH₂). Anal. calc. for C₃₇H₄₀N₈O₁₄ · H₂O (838.8): C 52.98, H 5.05, N 13.36; found: C 53.10, H 4.97, N 12.80.

3'-O-[5-[(9H-Fluoren-9-ylmethoxy)carbonyl]pentyl]-N⁶,2'-O-bis[2-(4-nitrophenyl)ethoxycarbonyl]adenosine (**40**). As described for **37**, with **36** (95 mg, 78 μ mol) in MeOH/CHCl₃ 4:1 (1 ml) containing 2% of TsOH. FC (silica gel (3 g), 1.5 \times 6 cm; CH₂Cl₂ (25 ml), CH₂Cl₂/MeOH 99:1 (25 ml), 98:2 (25 ml), 97:3 (25 ml)) gave 69 mg (92%) of **40**. Colourless foam. TLC (CH₂Cl₂/MeOH 95:5): *R*_f 0.52. UV (CH₂Cl₂): 298 (sh, 4.16), 288 (sh, 4.34), 266 (4.76). ¹H-NMR ((D₆)DMSO): 10.64 (s, NH); 8.66, 8.61 (2s, H-C(2), H-C(8)); 8.17–8.10 (m, 4 H *o* to NO₂); 7.87 (d, 2 H of fm); 7.64–7.30 (m, 6 H of fm, 4 H *m* to NO₂); 6.23 (d, *J* = 4.6, H-C(1')); 5.68 (dd, H-C(2')); 5.28 (t, OH-C(5')); 4.42–4.31 (m, H-C(3'), CH₂O of fm, 2 CH₂CH₂O of npeoc); 4.23 (t, H-C(9) of fm); 4.02 (m, H-C(4')); 3.78–3.30 (m, CH₂O-C(3'), 2 H-C(5')); 3.12–3.01 (m, 2 CH₂CH₂O of npeoc); 2.25 (t, CH₂COO); 1.45–1.10 (m, 3 CH₂). Anal. calc. for C₄₈H₄₇N₇O₁₄ · H₂O (964.0): C 59.80, H 5.12, N 10.17; found: C 60.01, H 5.04, N 10.08.

3'-O-(11-Hydroxyundecyl)-5'-O-[(4-methoxyphenyl)diphenylmethyl]-N⁶,2'-O-bis[2-(4-nitrophenyl)ethoxycarbonyl]adenosine (**41**). At r.t., **33** (0.11 g, 94 μ mol) was treated with 0.5M hydrazine hydrate soln. in pyridine/AcOH 4:1 (2 ml) for 4 min. Then acetone (2 ml) was added, the soln. evaporated and co-evaporated with toluene (3 \times 5 ml), the residue dissolved in CHCl₃ (50 ml), and the soln. washed with sat. NaCl soln. (3 \times 50 ml). The aq. phase was re-extracted with CHCl₃ (3 \times 50 ml), the org. layer dried (Na₂SO₄) and evaporated, and the residue purified by FC (silica gel (5 g), 1.5 \times 10 cm; CH₂Cl₂ (50 ml), CH₂Cl₂/MeOH 99:1 (50 ml), 98:2 (50 ml)): 98 mg (94%) of **41**. Colourless foam. TLC (CH₂Cl₂/MeOH 95:5): *R*_f 0.50. UV (MeOH): 266 (4.57), 234 (4.36). ¹H-NMR ((D₆)DMSO): 10.67 (s, NH); 8.60, 8.59 (2s, H-C(2), H-C(8)); 8.15 (d, 4 H *o* to NO₂); 7.61–7.51 (m, 4 H *m* to NO₂); 7.30–7.12 (m, 12 H of MeOTr); 6.80 (d, 2 H *o* to MeO); 6.27 (d, *J* = 2.8, H-C(1')); 5.95 (dd, H-C(2')); 4.72 (m, H-C(3')); 4.40–4.34 (m, 2 CH₂CH₂O of npeoc, OH); 4.05 (m, H-C(4')); 3.70 (s, MeO); 3.40 (m, CH₂O-C(3'), CH₂OH); 3.10 (m, 2 H-C(5')), 2 CH₂CH₂O of npeoc); 1.36–1.13 (m, 9 CH₂). Anal. calc. for C₅₉H₆₅N₇O₁₄ · H₂O (1114.2): C 63.60, H 6.06, N 8.80; found: C 63.58, H 5.94, N 8.75.

3'-Deoxy-5'-O-[(4-methoxyphenyl)diphenylmethyl]-N⁶-[2-(4-nitrophenyl)ethoxycarbonyl]adenyl-2'-{O^p-[2-(4-nitrophenyl)ethyl]} → 5'-3'-deoxy-N⁶-[2-(4-nitrophenyl)ethoxycarbonyl]adenyl-2'-{O^p-[2-(4-nitrophenyl)ethyl]} → 5'-3'-O-[1-[(1,4-dioxopentyl)oxy]undecyl]-N⁶,2'-O-bis[2-(4-nitrophenyl)ethoxycarbonyl]adenosine (**42**). A soln. of **37** (74 mg, 80 μ mol), 3'-deoxy-5'-O-[(4-methoxyphenyl)diphenylmethyl]-N⁶-[2-(4-nitrophenyl)ethoxycarbonyl]adenyl-2'-{O^p-[2-(4-nitrophenyl)ethyl]} → 5'-3'-deoxy-N⁶-[2-(4-nitrophenyl)ethoxycarbonyl]adenosine 2'-[2-(4-nitrophenyl)ethyl *N,N*-diisopropylphosphoramidite] (**1**) [15] (240 mg, 0.14 mmol), and 1*H*-tetrazole (28 mg, 0.40 mmol) in abs. MeCN (7 ml) was stirred under N₂ at r.t. for 4 h. Then it was oxidized with I₂ (500 mg) in pyridine (3 ml), CH₂Cl₂ (1 ml), and H₂O (1 ml) until no colour change was detected. The mixture was stirred for 15 min, diluted with CHCl₃ (50 ml), and washed with sat. Na₂S₂O₃/NaCl soln. (3 \times 50 ml). The aq. phase was re-extracted with CHCl₃ (3 \times 50 ml), the combined org. layer dried (Na₂SO₄), evaporated, and co-evaporated with toluene (3 \times 10 ml), and the residue purified by FC (silica gel (10 g), 2.5 \times 8 cm; CH₂Cl₂ (100 ml), CH₂Cl₂/MeOH 99:1 (100 ml), 98:2 (100 ml), 97:3 (100 ml), 96:4 (100 ml)): 190 mg (93%) of **42**. Colourless foam. TLC (CH₂Cl₂/MeOH 95:5): *R*_f 0.44. UV (CH₂Cl₂): 267 (5.00). ¹H-NMR (CDCl₃): 8.90–7.98 (m, 3 H-C(2), 3 H-C(8), 3 NH, 12 H *o* to NO₂); 7.41–7.11 (m, 12 H *m* to NO₂, 12 H of MeOTr); 6.77 (d, 2 H *o* MeO); 6.14–5.95 (m, 3 H-C(1')); 5.75–5.25 (m, 3 H-C(2')); 4.55–4.10 (m, 2 CH₂CH₂O of npe, H-C(3'), 3 H-C(4'), 4 CH₂CH₂O of npeoc, 4 H-C(5')); 4.04 (t, CH₂Olev); 3.73 (s, MeO); 3.50–3.25 (m, CH₂O-C(3'), 2 H-C(5')); 3.19–3.00 (m, 2 CH₂CH₂O of npe, 4 CH₂CH₂O of npeoc); 2.72 (t, CH₂COO); 2.56 (t, CH₂CO); 2.50–2.10 (m, 4 H-C(3')); 2.18 (s, Me); 1.55–1.20 (m, 9 CH₂). Anal. calc. for C₁₁₈H₁₂₃N₂₁O₃₈P₂ (2505.3): C 56.57, H 4.95, N 11.74; found: C 56.10, H 5.01, N 11.21.

3'-Deoxy-5'-O-[(4-methoxyphenyl)diphenylmethyl]-N⁶-[2-(4-nitrophenyl)ethoxycarbonyl]adenyl-2'-{O^p-[2-(4-nitrophenyl)ethyl]} → 5'-3'-deoxy-N⁶-[2-(4-nitrophenyl)ethoxycarbonyl]adenyl-2'-{O^p-[2-(4-nitrophenyl)ethyl]} → 5'-3'-O-[2-2-[(1,4-dioxopentyl)oxy]ethoxy]ethyl]-N⁶,2'-O-bis[2-(4-nitrophenyl)ethoxycarbonyl]adenosine (**43**). As described for **42**, with **38** (51 mg, 61 μ mol), **1** [15] (180 mg, 0.11 mmol), 1*H*-tetrazole (23 mg, 0.31 mmol), and abs. MeCN (5 ml). Workup and purification by FC (silica gel (5 g), 1.5 \times 10 cm; CH₂Cl₂ (50 ml), CH₂Cl₂/MeOH 99:1 (50 ml), 98:2 (50 ml), 97:3 (50 ml), 96:4 (50 ml)) yielded 140 mg (94%) of **43**. Colourless foam. TLC (CH₂Cl₂/MeOH 95:5): *R*_f 0.31. UV (CH₂Cl₂): 267 (5.01). ¹H-NMR ((D₆)DMSO): 10.58–10.49 (m, 3 NH); 8.60–8.40 (m, 3 H-C(2), 3 H-C(8)); 8.13–7.95 (m, 12 H *o* to NO₂); 7.60–7.32 (m, 12 H *m* to NO₂); 7.28–7.09 (m, 12 H of MeOTr); 6.76 (d, 2 H *o* to MeO); 6.24–6.10 (m, 3 H-C(1')); 5.71, 5.39, 5.38 (m, 3 H-C(2')); 4.50–4.02 (m, 2 CH₂CH₂O of npe, H-C(3'), 3 H-C(4'), 4 CH₂CH₂O of npeoc, 4 H-C(5'), CH₂Olev); 3.72 (s, MeO); 3.63–3.40 (m, 2 CH₂O, CH₂O-C(3')); 3.15–2.88 (m, 2 H-C(5'), 2 CH₂CH₂O of npe, 4 CH₂CH₂O of npeoc); 2.63 (t, CH₂COO); 2.39 (t, CH₂CO); 2.20–2.10 (m, 4 H-C(3')); 2.08 (s, Me). Anal. calc. for C₁₁₁H₁₀₉N₂₁O₃₉P₂ (2423.2): C 55.02, H 4.53, N 12.14; found: C 54.74, H 4.59, N 11.92.

3'-Deoxy-5'-O-[(4-methoxyphenyl)diphenylmethyl]-N⁶-[2-(4-nitrophenyl)ethoxycarbonyl]adenyl-2'-{O^p-[2-(4-nitrophenyl)ethyl]} → 5'-3'-deoxy-N⁶-[2-(4-nitrophenyl)ethoxycarbonyl]adenyl-2'-{O^p-[2-(4-nitro-

phenyl]ethyl]} \rightarrow 5'-3'-O-[(11-hydroxyundecyl)-N⁶,2'-O-bis[2-(4-nitrophenyl)ethoxycarbonyl]adenosine (**44**). As described for **41**, with **42** (90 mg, 36 μ mol) and 0.5M hydrazine hydrate soln. in pyridine/AcOH 4:1 (1 ml). The reaction was stopped after 6 min with acetone (1 ml) and the mixture evaporated. The crude product was purified by prep. TLC (silica gel, 40 \times 20 cm, CH₂Cl₂/MeOH 95:5): 81 mg (94%) of **44**. Colourless foam. TLC (CH₂Cl₂/MeOH 95:5): *R_f* 0.32. UV (CH₂Cl₂): 266(5.00). ¹H-NMR ((D₆)DMSO): 10.65–10.60 (*m*, 3 NH); 8.58–8.45 (*m*, 3 H–C(2), 3 H–C(8)); 8.15–7.98 (*m*, 12 H *o* to NO₂); 7.60–7.33 (*m*, 12 H *m* to NO₂); 7.24–7.08 (*m*, 12 H of MeOTr); 6.77 (*d*, 2 H *o* to MeO); 6.28–6.08 (*m*, 3 H–C(1')); 5.74, 5.59, 5.37 (*m*, 3 H–C(2')); 4.50–4.15 (*m*, 2 CH₂CH₂O of npe, H–C(3'), 3 H–C(4'), 4CH₂CH₂O of npeoc, 4 H–C(5'), OH); 3.78 (*s*, MeO); 3.40–3.30 (*m*, CH₂OH, CH₂O–C(3')); 3.15–2.90 (*m*, 2 H–C(5'), 2 CH₂CH₂O of npe, 4 CH₂CH₂O of npeoc); 2.60–2.15 (*m*, 4 H–C(3')); 1.39–1.11 (*m*, 9 CH₂). Anal. calc. for C₁₁₃H₁₁₇N₂₁O₃₆P₂ (2407.2): C 56.38, H 4.90, N 12.22; found: C 55.62, H 5.19, N 11.83.

3'-Deoxy-5'-O-[(4-methoxyphenyl)diphenylmethyl]-N⁶,2'-[2-(4-nitrophenyl)ethoxycarbonyl]adenylyl-[2'-{OP-[2-(4-nitrophenyl)ethyl]} \rightarrow 5'}-3'-deoxy-N⁶,2'-[2-(4-nitrophenyl)ethoxycarbonyl]adenylyl-[2'-{OP-[2-(4-nitrophenyl)ethyl]} \rightarrow 5'}-3'-O-[2-(2-hydroxyethoxy)ethyl]-N⁶,2'-O-bis[2-(4-nitrophenyl)ethoxycarbonyl]adenosine (**45**). As described for **41**, with **43** (100 mg, 42 μ mol) and 0.5M hydrazine hydrate soln. in pyridine/acetic acid 4:1 (2 ml). The crude product was dissolved in CH₂Cl₂ (50 ml) and washed with phosphate buffer pH 7 (3 \times 50 ml). Then the aq. phases were re-extracted with CH₂Cl₂ (3 \times 50 ml). The combined org. layer was dried (Na₂SO₄) and evaporated and the residue purified by FC (silica gel (5 g), 1.5 \times 8 cm; CH₂Cl₂ (50 ml), CH₂Cl₂/MeOH 99:1 (50 ml), 98:2 (50 ml), 97:3 (50 ml), 96:4 (50 ml)): 75 mg (77%) of **45**. Colourless foam. TLC (CH₂Cl₂/MeOH 95:5): *R_f* 0.24. UV (CH₂Cl₂): 267(5.01). ¹H-NMR ((D₆)DMSO): 10.64–10.56 (*m*, 3 NH); 8.60–8.42 (*m*, 3 H–C(2), 3 H–C(8)); 8.15–7.98 (*m*, 12 H *o* to NO₂); 7.60–7.09 (*m*, 12 H *m* to NO₂, 12 H of MeOTr); 6.76 (*d*, 2 H *o* to MeO); 6.27–6.10 (*m*, 3 H–C(1')); 5.72, 5.50, 5.38 (3*m*, 3 H–C(2')); 4.56–4.15 (*m*, 2 CH₂CH₂O of npe, H–C(3'), 3 H–C(4'), 4 CH₂CH₂O of npeoc, 4 H–C(5'), OH); (*s*, MeO); 3.58–3.35 (*m*, 2 CH₂O, CH₂OH, CH₂O–C(3')); 3.15–2.90 (*m*, 2 H–C(5'), 2 CH₂CH₂O of npe, 4 CH₂CH₂O of npeoc); 2.62–2.15 (*m*, 4 H–C(3')). Anal. calc. for C₁₀₆H₁₀₃N₂₁O₃₇P₂ (2325.1): C 54.76, H 4.47, N 12.65; found: C 54.25, H 4.66, N 12.34.

3'-O-(5-Carboxypentyl)-5'-O-[(4-methoxyphenyl)diphenylmethyl]-N⁶,2'-O-bis[2-(4-nitrophenyl)ethoxycarbonyl]adenosine Triethylammonium Salt (**46** · Et₃N). At r.t., **36** (40 mg, 33 μ mol) was treated with 3% piperidine/DMF (1 ml) for 10 min, then dissolved in AcOEt (20 ml), and washed with phosphate buffer pH 7 (3 \times 20 ml). The aq. phase was re-extracted with AcOEt (3 \times 20 ml), the org. layer dried (Na₂SO₄) and evaporated, and the residue purified by FC (silica gel (3 g), 1.5 \times 6 cm; CH₂Cl₂/Et₃N 99:1 (50 ml), CH₂Cl₂/MeOH/Et₃N 98:1:1 (50 ml), 97:2:1 (50 ml), 96:3:1 (50 ml)): 28 mg (75%) of **46**. Colourless foam. TLC (CH₂Cl₂/MeOH 9:1): *R_f* 0.71. UV (CH₂Cl₂): 267(4.57), 233(4.37). ¹H-NMR ((D₆)DMSO): 10.60 (*br. s*, NH); 8.62, 8.61 (2*s*, H–C(2), H–C(8)); 8.15 (*d*, 4 H *o* to NO₂); 7.61–7.52 (*m*, 4 H *m* to NO₂); 7.30–7.12 (*m*, 12 H of MeOTr); 6.89 (*d*, 2 H *o* to MeO); 6.28 (*d*, *J* = 2.4, H–C(1')); 5.94 (*dd*, H–C(2')); C(2')); 4.70 (*m*, H–C(3')); 4.41–4.35 (*m*, 2CH₂CH₂O of npeoc); 4.05 (*m*, H–C(4')); 3.70 (*s*, MeO); 3.50–3.30 (*m*, CH₂O–C(3'), 2 H–C(5')); 3.15–3.03 (*m*, 2 CH₂CH₂O of npeoc); 2.62 (*q*, 3 MeCH₂); 2.12 (*t*, CH₂COO); 1.50–1.12 (*m*, 3 CH₂); 1.02 (*t*, 3 MeCH₂). Anal. calc. for C₅₄H₅₃N₇O₁₅ · Et₃N (1141.2): C 63.15, H 6.01, N 9.82; found: C 63.05, H 6.52, N 9.30.

3'-Deoxy-5'-O-[(4-methoxyphenyl)diphenylmethyl]-N⁶,2'-[2-(4-nitrophenyl)ethoxycarbonyl]adenylyl-[2'-{OP-[2-(4-nitrophenyl)ethyl]} \rightarrow 5'}-3'-deoxy-N⁶,2'-[2-(4-nitrophenyl)ethoxycarbonyl]adenylyl-[2'-{OP-[2-(4-nitrophenyl)ethyl]} \rightarrow 5'}-3'-O-[5-(2-cyanoethoxycarbonyl)pentyl]-N⁶,2'-O-bis[2-(4-nitrophenyl)ethoxycarbonyl]adenosine (**47**). As described for **42**, with **39** (53 mg, 63 μ mol), **1** [15] (190 mg, 0.11 mmol), 1H-tetrazole (24 mg, 0.34 mmol), and abs. MeCN (5 ml). Workup and purification by FC (silica gel (10 g), 2 \times 13 cm; CH₂Cl₂ (100 ml), CH₂Cl₂/MeOH 99:1 (100 ml), 98:2 (100 ml), 97:3 (100 ml), 96:4 (100 ml)) gave 144 mg (95%) of **47**. Colourless foam. TLC (CHCl₃/MeOH 9:1): *R_f* 0.66. UV (CH₂Cl₂): 267(5.02). ¹H-NMR ((D₆)DMSO): 10.62–10.58 (*m*, 3 NH); 8.59–8.44 (*m*, 3 H–C(2), 3 H–C(8)); 8.17–7.88 (*m*, 12 H *o* to NO₂); 7.60–7.35 (*m*, 12 H *m* to NO₂); 7.25–7.10 (*m*, 12 H of MeOTr); 6.76 (*d*, 2 H *o* to MeO); 6.25–6.10 (*m*, 3 H–C(1')); 5.75, 5.59, 5.38 (*m*, 3 H–C(2')); 4.40–4.10 (*m*, 2 CH₂CH₂O of npe, H–C(3'), 3 H–C(4'), 4 CH₂CH₂O of npeoc, 4 H–C(5'), CH₂OCO); 3.79 (*s*, MeO); 3.45–3.35 (*m*, CH₂O–C(3')); 3.13–2.89 (*m*, 2 H–C(5'), 2 CH₂CH₂O of npe, 4 CH₂CH₂O of npeoc); 2.84 (*t*, CH₂CN); 2.30–2.10 (*m*, 4 H–C(3'), CH₂COO); 1.50–1.10 (*m*, 3 CH₂). Anal. calc. for C₁₁₁H₁₀₈N₂₂O₃₇P₂ (2404.2): C 55.45, H 4.53, N 12.82; found: C 55.35, H 4.79, N 11.99.

3'-Deoxy-5'-O-[(4-methoxyphenyl)diphenylmethyl]-N⁶,2'-[2-(4-nitrophenyl)ethoxycarbonyl]adenylyl-[2'-{OP-[2-(4-nitrophenyl)ethyl]} \rightarrow 5'}-3'-deoxy-N⁶,2'-[2-(4-nitrophenyl)ethoxycarbonyl]adenylyl-[2'-{OP-[2-(4-nitrophenyl)ethyl]} \rightarrow 5'}-3'-O-[{(9H-fluoren-9-ylmethoxy)carbonyl]pentyl]-N⁶,2'-O-bis[2-(4-nitrophenyl)ethoxycarbonyl]adenosine (**48**). As described for **42**, with **40** (46 mg, 48 μ mol), **1** [15] (133 mg, 80 μ mol), 1H-tetrazole (13 mg, 0.19 mmol), and abs. MeCN (3 ml). Workup and purification by FC (silica gel (5 g) 1.5 \times 10 cm; (50 ml), CH₂Cl₂/MeOH 99:1 (50 ml), 98:2 (50 ml), 97:3 (50 ml), 96:5 (50 ml)) yielded 110 mg (89%) of **48**. Colourless

foam. TLC ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ 95:5): R_f 0.30. UV (CH_2Cl_2): 297 (sh, 4.57), 267 (5.11). $^1\text{H-NMR}$ ($(\text{D}_6)\text{DMSO}$): 10.72–10.58 (m , 3 NH); 8.60–8.42 (m , 3 H–C(2), 3 H–C(8)); 8.15–7.98 (m , 12 H o to NO_2); 7.75 (d , 2 H of fm); 7.60–7.10 (m , 12 H m to NO_2 , 8 H of fm, 12 H of MeOTr); 6.78 (d , 2 H o to MeO); 6.26–6.10 (m , 3 H–C(1')); 5.74, 5.48, 5.38 (m , 3 H–C(2')); 4.44–4.10 (m , $2\text{CH}_2\text{CH}_2\text{O}$ of npe, H–C(3'), 3 H–C(4'), $4\text{CH}_2\text{CH}_2\text{O}$ of npeoc, 4 H–C(5'), CH_2O of fm, H–C(9) of fm); 3.78 (s , MeO); 3.40–2.88 (m , CH_2O –C(3'), 2 H–C(5'), $2\text{CH}_2\text{CH}_2\text{O}$ of npe, $4\text{CH}_2\text{CH}_2\text{O}$ of npeoc); 2.60–2.10 (m , 4 H–C(3'), CH_2COO); 1.40–1.02 (m , 3 CH_2). Anal. calc. for $\text{C}_{122}\text{H}_{115}\text{N}_{21}\text{O}_{37}\text{P}_2$ (2529.3): C 57.93, H 4.58, N 11.63; found: C 57.43, H 4.84, N 11.38.

3'-Deoxy-5'-O-[2-(4-methoxyphenyl)diphenylmethyl]-N⁶-[2-(4-nitrophenyl)ethoxycarbonyl]adenylyl-2'-[O^p-[2-(4-nitrophenyl)ethyl]] → 5'-3'-deoxy-N⁶-[2-(4-nitrophenyl)ethoxycarbonyl]adenylyl-2'-[O^p-[2-(4-nitrophenyl)ethyl]] → 5'-3'-O-(5-carboxypentyl)-N⁶,2'-O-bis[2-(4-nitrophenyl)ethoxycarbonyl]adenosine (49). As described for 46, with 48 (255 mg, 100 μmol) and 3% piperidine/DMF (2.5 ml). Workup and purification by FC (silica gel (5 g), 1.5×7 cm; CH_2Cl_2 (50 ml), $\text{CH}_2\text{Cl}_2/\text{MeOH}$ 99:1 (50 ml), 98:2 (50 ml), 97:3 (50 ml), 96:4 (50 ml), 95:5 (50 ml), 94:6 (50 ml)) gave 210 mg (87%) of 49. Colourless foam. TLC ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ 9:1): R_f 0.58. UV (CH_2Cl_2): 267 (5.01), 271 (sh, 4.93). $^1\text{H-NMR}$ ($(\text{D}_6)\text{DMSO}$): 12.00 (br. s , COOH); 10.60 (m , 3 NH); 8.61–8.44 (m , 3 H–C(2), 3 H–C(8)); 8.13–7.98 (m , 12 H o to NO_2); 7.61–7.08 (m , 12 H m to NO_2 , 12 H of MeOTr); 6.77 (d , 2 H o to MeO); 6.26–6.09 (m , 3 H–C(1')); 5.73, 5.48, 5.36 ($3m$, 3 H–C(2')); 4.44–4.13 (m , $2\text{CH}_2\text{CH}_2\text{O}$ of npe, H–C(3'), 3 H–C(4'), $4\text{CH}_2\text{CH}_2\text{O}$ of npeoc, 4 H–C(5')); 3.69 (s , MeO); 3.50–3.40 (m , CH_2O –C(3')); 3.17–2.90 (m , 2 H–C(5'), $2\text{CH}_2\text{CH}_2\text{O}$ of npe, $4\text{CH}_2\text{CH}_2\text{O}$ of npeoc); 2.62–2.10 (m , 4 H–C(3'), CH_2COO); 1.46–1.15 (m , 3 CH_2). Anal. calc. for $\text{C}_{108}\text{H}_{105}\text{N}_{21}\text{O}_{37}\text{P}_2$ (2351.1): C 55.17, H 4.50, N 12.51; found: C 55.28, H 4.79, N 12.01.

3'-Deoxy-N⁶-[2-(4-nitrophenyl)ethoxycarbonyl]adenylyl-2'-[O^p-[2-(4-nitrophenyl)ethyl]] → 5'-3'-deoxy-N⁶-[2-(4-nitrophenyl)ethoxycarbonyl]adenylyl-2'-[O^p-[2-(4-nitrophenyl)ethyl]] → 5'-3'-O-(11-hydroxyundecyl)-N⁶,2'-O-bis[2-(4-nitrophenyl)ethoxycarbonyl]adenosine (50). A soln. of 44 (53 mg, 22 μmol) in 80% AcOH/ H_2O (1 ml) was stirred at r.t. for 1 d, then evaporated, and co-evaporated with H_2O (3 \times 5 ml) and MeOH (3 \times 5 ml). The residue was purified by FC (silica gel (3 g) 1.5×5 cm; CH_2Cl_2 (25 ml), $\text{CH}_2\text{Cl}_2/\text{MeOH}$ 99:1 (25 ml), 98:2 (25 ml), 97:3 (25 ml), 96:4 (25 ml), 95:5 (25 ml), 94:6 (25 ml)): 35 mg (75%) of 50. Colourless foam. TLC ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ 9:1): R_f 0.52. UV (CH_2Cl_2): 266 (5.02). $^1\text{H-NMR}$ ($(\text{D}_6)\text{DMSO}$): 10.69 (m , 3 NH); 8.63–8.45 (m , 3 H–C(2), 3 H–C(8)); 8.14–7.99 (m , 12 H o to NO_2); 7.59–7.35 (m , 12 H m to NO_2); 6.25–6.15 (m , 3 H–C(1')); 5.76, 5.42, 5.25 (m , 3 H–C(2')); 5.12 (t , OH–C(5')); 4.40–4.15 (m , $2\text{CH}_2\text{CH}_2\text{O}$ of npe, H–C(3'), 3 H–C(4'), $4\text{CH}_2\text{CH}_2\text{O}$ of npeoc, 4 H–C(5'), OH); 3.72–3.31 (m , CH_2OH , CH_2O –C(3'), 2 H–C(5')); 3.13–2.90 (m , $2\text{CH}_2\text{CH}_2\text{O}$ of npe, $4\text{CH}_2\text{CH}_2\text{O}$ of npeoc); 2.50–1.90 (m , 4 H–C(3')); 1.48–1.13 (m , 9 CH_2). Anal. calc. for $\text{C}_{93}\text{H}_{101}\text{N}_{21}\text{O}_{35}\text{P}_2$ (2134.9): C 52.32, H 4.77, N 13.78; found: C 51.94, H 4.98, N 13.09.

3'-Deoxy-N⁶-[2-(4-nitrophenyl)ethoxycarbonyl]adenylyl-2'-[O^p-[2-(4-nitrophenyl)ethyl]] → 5'-3'-deoxy-N⁶-[2-(4-nitrophenyl)ethoxycarbonyl]adenylyl-2'-[O^p-[2-(4-nitrophenyl)ethyl]] → 5'-3'-O-[2-(2-hydroxyethoxy)ethyl]-N⁶,2'-O-bis[2-(4-nitrophenyl)ethoxycarbonyl]adenosine (51). As described for 37, with 45 (240 mg, 100 μmol) in MeOH/ CHCl_3 4:1 (1 ml) containing 2% of TsOH. Workup and FC (silica gel (5 g), 1.5×10 cm; CH_2Cl_2 (50 ml), $\text{CH}_2\text{Cl}_2/\text{MeOH}$ 99:1 (50 ml), 98:2 (50 ml), 97:3 (50 ml), 96:4 (50 ml), 95:5 (50 ml), 94:6 (50 ml)) gave 160 mg (76%) of 51. Colourless foam. TLC ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ 95:5): R_f 0.35. UV (CH_2Cl_2): 267 (5.02). $^1\text{H-NMR}$ ($(\text{D}_6)\text{DMSO}$): 10.68–10.65 (m , 3 NH); 8.73–8.47 (m , 3 H–C(2), 3 H–C(8)); 8.16–8.01 (m , 12 H o to NO_2); 7.62–7.44 (m , 12 H m to NO_2); 6.25–6.15 (m , 3 H–C(1')); 5.72, 5.40, 5.26 ($3m$, 3 H–C(2')); 5.11 (t , OH–C(5')); 4.60–4.10 (m , $2\text{CH}_2\text{CH}_2\text{O}$ of npe, H–C(3'), 3 H–C(4'), $4\text{CH}_2\text{CH}_2\text{O}$ of npeoc, 4 H–C(5'), OH); 3.70–3.32 (m , $2\text{CH}_2\text{O}$, CH_2OH , CH_2O –C(3'), 2 H–C(5')); 3.12–2.89 (m , $2\text{CH}_2\text{CH}_2\text{O}$ of npe, $4\text{CH}_2\text{CH}_2\text{O}$ of npeoc); 2.45–2.00 (m , 4 H–C(3')). Anal. calc. for $\text{C}_{86}\text{H}_{87}\text{N}_{21}\text{O}_{36}\text{P}_2$ (2052.7): C 50.32, H 4.27, N 14.33; found: C 49.86, H 4.38, N 13.64.

3'-Deoxy-N⁶-[2-(4-nitrophenyl)ethoxycarbonyl]adenylyl-2'-[O^p-[2-(4-nitrophenyl)ethyl]] → 5'-3'-deoxy-N⁶-[2-(4-nitrophenyl)ethoxycarbonyl]adenylyl-2'-[O^p-[2-(4-nitrophenyl)ethyl]] → 5'-3'-O-[5-(2-cyanoxyethoxycarbonyl)pentyl]-N⁶,2'-O-bis[2-(4-nitrophenyl)ethoxycarbonyl]adenosine (52). As described for 37, with 47 (120 mg, 52 μmol) in MeOH/ CHCl_3 4:1 (1 ml) containing 2% of TsOH. Workup after 2 h reaction time and FC (silica gel (5 g), 1.5×10 cm; CH_2Cl_2 (50 ml), $\text{CH}_2\text{Cl}_2/\text{MeOH}$ 99:1 (50 ml), 98:2 (50 ml), 97:3 (50 ml), 96:4 (50 ml), 95:5 (50 ml)) gave 88 mg (80%) of 52. Colourless foam. TLC ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ 9:1): R_f 0.48. UV (CH_2Cl_2): 267 (5.02). $^1\text{H-NMR}$ ($(\text{D}_6)\text{DMSO}$): 10.57–10.53 (m , 3 NH); 8.60–8.45 (m , 3 H–C(2), 3 H–C(8)); 8.16–7.99 (m , 12 H o to NO_2); 7.61–7.46 (m , 12 H m to NO_2); 6.25–6.14 (m , 3 H–C(1')); 5.74, 5.40, 5.26 ($3m$, 3 H–C(2')); 5.08 (t , OH–C(5')); 4.45–4.15 (m , $2\text{CH}_2\text{CH}_2\text{O}$ of npe, H–C(3'), 3 H–C(4'), $4\text{CH}_2\text{CH}_2\text{O}$ of npeoc, 4 H–C(5'), CH_2OCO); 3.70–3.39 (m , CH_2O –C(3'), 2 H–C(5')); 3.15–2.90 (m , $2\text{CH}_2\text{CH}_2\text{Cl}_2\text{O}$ of npe, $4\text{CH}_2\text{CH}_2\text{O}$ of npeoc); 2.87 (t , CH_2CN); 2.45–2.03 (m , 4 H–C(3'), CH_2COO); 1.50–1.20 (m , 3 CH_2). Anal. calc. for $\text{C}_{91}\text{H}_{92}\text{N}_{22}\text{O}_{36}\text{P}_2$ (2131.8): C 51.27, H 4.35, N 14.45; found: C 50.89, H 4.47, N 14.16.

3'-Deoxyadenylyl-(2' → 5')-3'-deoxyadenylyl-(2' → 5')-3'-O-(11-hydroxyundecyl)adenosine Bis(1.8-diazabicyclo[5.4.0]undec-7-enium) Salt (53). After co-evaporation with dry pyridine (3 × 5 ml), **50** (32 mg, 15 μmol) was dissolved in 0.5M DBU/pyridine (1 ml) and stirred at r.t. for 3 d, then neutralized with 1M AcOH, evaporated, and co-evaporated with toluene (3 × 5 ml). The residue was washed and centrifugated several times with MeCN: 19 mg (70%) of **53**. Colourless powder. HPLC: (A 0.1M (Et₃NH)OAc buffer (pH 7), B 0.1M (Et₃NH)OAc buffer/MeCN 1:1, C MeCN; gradient: 0–20 min 90% A in B → 100% B, 20–40 min 100% B → 100% C): *t_R* 14.40 min. ¹H-NMR (D₂O): 8.12, 8.03, 7.98, 7.93, 7.83, 7.75 (6s, 3 H–C(2), 3 H–C(8)); 6.02, 5.79 (2s, 2 H–C(1')); 5.72 (*d*, *J* = 5.7, H–C(1')); 5.10 (br. *s*, H–C(2')); 4.67–4.00 (*m*, 2 H–C(2'), H–C(3'), 3 H–C(4'), 4 H–C(5')); 4.07–3.45 (*m*, CH₂OH, CH₂O–C(3'), 2 H–C(5'), 4 H–C(2), of DBU, 4 H–C(11) of DBU); 3.29 (*t*, 4 H–C(9) of DBU); 2.60 (*m*, 4 H–C(6) of DBU); 2.50–2.33 (*m*, 4 H–C(3')); 2.00 (*m*, 4 H–C(10) of DBU); 1.75–1.48 (*m*, 4 H–C(3) of DBU, 4 H–C(4) of DBU, 4 H–C(5)); 1.25 (br. *s*, 9 CH₂).

3'-Deoxyadenylyl-(2' → 5')-3'-deoxyadenylyl-(2' → 5')-3'-O-[2-(2-hydroxyethoxy)ethyl]adenosine Bis(1.8-diazabicyclo[5.4.0]undec-7-enium) Salt (54). As described for **53**, with **51** (135 mg, 66 μmol) and 0.5M DBU/pyridine (4 ml). The crude product was washed and centrifugated several times with MeCN: 100 mg (92%) of **54**. Colourless powder. HPLC: (see **53** for A, and B; gradient: 0–2 min 98% A in B, 2–20 min 98% A in B → 100% B, 20–25 min 100% B): *t_R* 10.55 min. ¹H-NMR (D₂O): 8.11, 8.01, 7.99, 7.88, 7.82, 7.74 (6s, 3 H–C(2), 3 H–C(8)); 6.02, 5.78 (2s, 2 H–C(1')); 5.69 (*d*, *J* = 5.8, H–C(1')); 5.05 (*m*, H–C(2')); 4.65–4.10 (*m*, 2 H–C(2'), H–C(3'), 3 H–C(4'), 4 H–C(5')); 3.84–3.40 (*m*, 2 CH₂O, CH₂OH, CH₂O–C(3'), 2 H–C(5'), 4 H–C(2) of DBU, 4 H–C(11) of DBU); 3.28 (*t*, 4 H–C(9) of DBU); 2.57–2.62 (*m*, 4 H–C(6) of DBU); 2.48–2.30 (*m*, 4 H–C(3')); 1.94–2.04 (*m*, 4 H–C(10) of DBU); 1.68 (*m*, 4 H–C(3) of DBU, 4 H–C(4) of DBU, 4 H–C(5)).

3'-Deoxyadenylyl-(2' → 5')-3'-deoxyadenylyl-(2' → 5')-3'-O-(5-carboxypentyl)adenosine Tris(1.8-diazabicyclo[5.4.0]undec-7-enium) Salt (55). As described for **53**, with **52** (11 mg, 5.2 μmol) and 0.5M DBU/pyridine (0.36 ml). The crude product was washed and centrifugated several times with MeCN: 8.3 mg (92%) of **55**. Colourless powder. HPLC: (see **53** for A–C; gradient: 0–20 min 90% A in B → 100% B, 20–40 min 100% B → 100% C): *t_R* 7.73 min. ¹H-NMR (D₂O): 8.10, 8.00, 7.97, 7.88, 7.80, 7.77 (6s, 3 H–C(2), 3 H–C(8)); 6.00, 5.77 (2s, 2 H–C(1')); 5.66 (*d*, *J* = 5.7, H–C(1')); 5.05 (br. *s*, H–C(2')); 4.65–4.00 (*m*, 2 H–C(2'), H–C(3'), 3 H–C(4'), 4 H–C(5')); 3.80–3.55 (*m*, CH₂O–C(3'), 2 H–C(5')); 3.52–3.40 (*m*, 6 H–C(2) of DBU, 6 H–C(11) of DBU); 3.19 (*t*, 6 H–C(9) of DBU); 2.55 (*m*, 6 H–C(6) of DBU); 2.44–2.30 (*m*, 4 H–C(3')); 2.25 (*t*, CH₂COO); 1.95 (*m*, 6 H–C(10) of DBU); 1.63 (*m*, 6 H–C(3) of DBU, 6 H–C(4) of DBU, 6 H–C(5)); 1.60–1.30 (br. *s*, 3 CH₂).

3'-Deoxy-5'-O-[(4-methoxyphenyl)diphenylmethyl]-N⁶-[2-(4-nitrophenyl)ethoxycarbonyl]adenylyl-{2'-{O^P-[2-(4-nitrophenyl)ethyl]} → 5'}-3'-deoxy-N⁶-[2-(4-nitrophenyl)ethoxycarbonyl]adenylyl-{2'-{O^P-[2-(4-nitrophenyl)ethyl]} → 5'}-3'-O-[11-(cholest-5-en-3β-yloxy)undecyl]-N⁶,2'-O-bis[2-(4-nitrophenyl)ethoxycarbonyl]adenosine (56). A mixture of **44** (64 mg, 27 μmol), DMAP (29 mg, 240 μmol), cholesteryl chloroformate (= cholest-5-en-3β-yl carbonochloridate; *Fluka*, 24 mg, 53 μmol), 1-methyl-1*H*-imidazole (4 μl, 50 μmol), and abs. CH₂Cl₂ (5 ml) was stirred at r.t. for 1 d, then more cholesteryl chloroformate (25 mg, 56 μmol) and 1-methyl-1*H*-imidazole (4 μl, 50 μmol) were added. The soln. was kept at r.t. for 8 h, then diluted with CH₂Cl₂ (50 ml), and washed with sat. NaCl soln. (3 × 50 ml). The aq. phase was re-extracted with CH₂Cl₂ (3 × 20 ml), the combined org. layer dried (Na₂SO₄) and evaporated, and the residue purified by FC (silica gel (10 g), 2 × 13 cm; CH₂Cl₂ (100 ml), CH₂Cl₂/MeOH 99:1 (100 ml), 98:2 (100 ml)); 55 mg (73%) of **56**. Colourless foam. TLC (CH₂Cl₂/MeOH 95:5): *R_f* 0.42. UV (CH₂Cl₂): 267(5.01). ¹H-NMR ((D₆)DMSO): 10.61–10.57 (*m*, 3 NH); 8.68–8.42 (*m*, 3 H–C(2), 3 H–C(8)); 8.10–7.95 (*m*, 12 H *o* to NO₂); 7.68–7.34 (*m*, 12 H *m* to NO₂); 7.25–7.08 (*m*, 12 H of MeOTr); 6.85 (*d*, 2 H *o* to MeO); 6.24–6.10 (*m*, 3 H–C(1')); 5.73, 5.49, 5.36 (*m*, 3 H–C(2')); 5.29 (*m*, H–C(6) of chol); 4.40–4.15 (*m*, 2 CH₂CH₂O of npe, H–C(3'), 3 H–C(4'), 4 CH₂CH₂O of npeoc, 4 H–C(5'), H–C(3) of chol); 3.99 (*t*, CH₂OCOchol); 3.78 (*s*, MeO); 3.30–3.40 (*m*, CH₂O–C(3')); 3.13–2.80 (*m*, 2 H–C(5'), 2 CH₂CH₂O of npe, 4 CH₂CH₂O of npeoc); 2.30–0.60 (*m*, 4 H–C(3'), 43 H of chol, 9 CH₂). Anal. calc. for C₁₄₁H₁₆₁N₂₁O₃₈P₂ (2819.9): C 60.06, H 5.75, N 10.43; found: C 60.47, H 6.06, N 10.20.

3'-Deoxy-5'-O-[(4-methoxyphenyl)diphenylmethyl]-N⁶-[2-(4-nitrophenyl)ethoxycarbonyl]adenylyl-{2'-{O^P-[2-(4-nitrophenyl)ethyl]} → 5'}-3'-deoxy-N⁶-[2-(4-nitrophenyl)ethoxycarbonyl]adenylyl-{2'-{O^P-[2-(4-nitrophenyl)ethyl]} → 5'}-3'-O-[2-(2-(cholest-5-en-3β-yloxy)ethoxy)ethyl]-N⁶,2'-O-bis[2-(4-nitrophenyl)ethoxycarbonyl]adenosine (57). As described for **56**, with **45** (570 mg, 250 μmol), DMAP (28 mg, 230 μmol), cholesteryl chloroformate (280 mg, 620 μmol), 1-methyl-1*H*-imidazole (50 μl, 630 μmol), and abs. CH₂Cl₂ (5 ml). After 16 h, more cholesteryl chloroformate (100 mg, 220 μmol) and 1-methyl-1*H*-imidazole (18 μl, 220 μmol) were added. The soln. was kept at r.t. for 8 h, then worked up and purified by FC (silica gel (20 g), 3 × 9 cm; CH₂Cl₂ (200 ml), CH₂Cl₂/MeOH 99:1 (200 ml), 98:2 (200 ml), 97:3 (200 ml)); 510 mg (76%) of **57**.

Colourless foam. TLC ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ 95:5): R_f 0.36. UV (CH_2Cl_2): 267 (5.01). $^1\text{H-NMR}$ ((D_6) DMSO): 10.65–10.60 (m , 3 H-NH); 8.60–8.45 (m , 3 $\text{H-C}(2)$, 3 $\text{H-C}(8)$); 8.15–7.98 (m , 12 $\text{H } o$ to NO_2); 7.60–7.12 (m , 12 $\text{H } m$ to NO_2 , 12 H of MeOTr); 6.78 (d , 2 $\text{H } o$ to MeO); 6.26–6.12 (m , 3 $\text{H-C}(1')$); 5.75, 5.50, 5.39 (m , 3 $\text{H-C}(2')$); 5.22 (m , $\text{H-C}(6)$ of chol); 4.55–4.12 (m , 2 $\text{CH}_2\text{CH}_2\text{O}$ of npe, $\text{H-C}(3')$, 3 $\text{H-C}(4')$, 4 $\text{CH}_2\text{CH}_2\text{O}$ of npeoc, 4 $\text{H-C}(5')$, $\text{CH}_2\text{OCOchol}$, $\text{H-C}(3)$ of chol); 3.68 (s , MeO); 3.65–3.47 (m , 2 CH_2O , $\text{CH}_2\text{O-C}(3')$); 3.16–2.91 (m , 2 $\text{H-C}(5')$, 2 $\text{CH}_2\text{CH}_2\text{O}$ of npe, 4 $\text{CH}_2\text{CH}_2\text{O}$ of npeoc); 2.65–0.55 (m , 4 $\text{H-C}(3)$, 43 H of chol). Anal. calc. for $\text{C}_{134}\text{H}_{147}\text{N}_{21}\text{O}_{39}\text{P}_2$ (2737.7): C 58.79, H 5.41, N 10.74; found: C 58.27, H 5.62, N 10.10.

3'-Deoxy-5'-O-[(4-methoxyphenyl)diphenylmethyl]-N⁶-[2-(4-nitrophenyl)ethoxycarbonyl]adenylyl-{2'-[O^p-[2-(4-nitrophenyl)ethyl]] → 5'}-3'-deoxy-N⁶-[2-(4-nitrophenyl)ethoxycarbonyl]adenylyl-{2'-[O^p-[2-(4-nitrophenyl)ethyl]] → 5'}-3'-O-[5-(cholest-5-en-3 β -yloxycarbonyl)pentyl]-N⁶,2'-O-bis[2-(4-nitrophenyl)ethoxycarbonyl]adenosine (**58**). As described for **15**, with **49** (10.5 mg, 4.5 μmol), EDC · HCl (6.1 mg, 32 μmol), DMAP (9.8 mg, 80 μmol), abs. CH_2Cl_2 (0.5 ml), and cholesterol (12 mg, 31 μmol). After 3 h reaction time, the soln. was worked up with CH_2Cl_2 (4 \times 20 ml) and phosphate buffer pH 7 (3 \times 20 ml). Purification by prep. TLC (silica gel, 20 \times 20 cm, $\text{CH}_2\text{Cl}_2/\text{MeOH}$ 95:5) gave 4.7 mg (40%) of **58**. Colourless foam. TLC ($\text{CH}_2\text{Cl}_2/\text{MeOH}$ 95:5): R_f 0.55. UV (CH_2Cl_2): 267 (5.00). $^1\text{H-NMR}$ ((D_6) DMSO): 10.62–10.55 (m , 3 NH); 8.60–8.44 (m , 3 $\text{H-C}(2)$, 3 $\text{H-C}(8)$); 8.12–7.95 (m , 12 $\text{H } o$ to NO_2); 7.57–7.10 (m , 12 $\text{H } m$ to NO_2 , 12 H of MeOTr); 6.75 (d , 2 $\text{H } o$ to MeO); 6.26–6.10 (m , 3 $\text{H-C}(1')$); 5.72, 5.49, 5.38 (m , 3 $\text{H-C}(2')$); 5.67 (s , CH_2Cl_2); 5.21 (m , $\text{H-C}(6)$ of chol); 4.44–4.14 (m , 2 $\text{CH}_2\text{CH}_2\text{O}$ of npe, $\text{H-C}(3')$, 3 $\text{H-C}(4')$, 4 $\text{CH}_2\text{CH}_2\text{O}$ of npeoc, 4 $\text{H-C}(5')$, $\text{H-C}(3)$ of chol); 3.68 (s , MeO); 3.15–2.88 (m , $\text{CH}_2\text{O-C}(3')$, 2 $\text{H-C}(5')$, 2 $\text{CH}_2\text{CH}_2\text{O}$ of npe, 4 $\text{CH}_2\text{CH}_2\text{O}$ of npeoc); 2.60–0.59 (m , CH_2COO , 4 $\text{H-C}(3')$, 43 H of chol, 3 CH_2). Anal. calc. for $\text{C}_{135}\text{H}_{149}\text{N}_{21}\text{O}_{37}\text{P}_2 \cdot 0.5 \text{CH}_2\text{Cl}_2$ (2762.2): C 58.92, H 5.47, N 10.65; found: C 58.29, H 5.56, N 10.36.

3'-Deoxyadenylyl-(2' → 5')-3'-deoxyadenylyl-(2' → 5')-3'-O-[11-(cholest-5-en-3 β -yloxycarbonyloxy)undecyl]adenosine Bis(1,8-diazobicyclo[5.4.0]undec-7-enium) Salt (**59**). A soln. of **56** (56 mg, 20 μmol) in $\text{MeOH}/\text{CHCl}_3$ 4:1 (1 ml) containing 2% of TsOH was stirred at r.t. for 60 min. The mixture was diluted with CH_2Cl_2 (20 ml) and washed with sat. NaHCO_3 soln. (3 \times 20 ml), the aq. phase re-extracted with CH_2Cl_2 (3 \times 20 ml), the org. layer dried (Na_2SO_4) and evaporated and the residue dissolved in CH_2Cl_2 and treated with Et_2O . A colourless powder was obtained on centrifugation. After co-evaporation with dry pyridine (3 \times 5 ml), this solid was dissolved in 0.5M DBU/MeCN (0.7 ml) and the soln. stirred at r.t. for 3 d, then neutralized with 1M AcOH, evaporated, and co-evaporated with toluene (3 \times 5 ml). The residue was washed and centrifugated several times with MeCN: 10 mg (42%) of **59**. Colourless powder. TLC ($\text{CH}_2\text{Cl}_2/\text{H}_2\text{O}/\text{MeOH}$ 50:20:4) R_f 0.40. HPLC (0.1M (Et_3NH)OAc buffer (pH 7)/THF/MeCN 15:10:75): t_R 9.04 min. $^1\text{H-NMR}$ ((D_6) DMSO with little CDCl_3): 8.50–8.10 (m , 3 $\text{H-C}(2)$, 3 $\text{H-C}(8)$); 7.20–7.10 (m , 3 NH_2); 6.15, 5.99 (2s, 2 $\text{H-C}(1')$); 5.90 (d , $J = 5.5$, $\text{H-C}(1')$); 5.46, 5.22, 5.02 (m , 3 $\text{H-C}(2')$); 5.31 (m , $\text{H-C}(6)$ of chol); 4.71 (m , $\text{H-C}(3')$); 4.33 (m , 3 $\text{H-C}(4')$, $\text{H-C}(3)$ of chol); 4.02 (t , CH_2OCO); 3.95–3.33 (m , 6 $\text{H-C}(5')$, $\text{CH}_2\text{O-C}(3')$, 4 $\text{H-C}(2)$ of DBU, 4 $\text{H-C}(11)$ of DBU, 4 $\text{H-C}(9)$ of DBU); 2.40–0.64 (m , 4 $\text{H-C}(6)$ of DBU, 4 $\text{H-C}(10)$ of DBU, 4 $\text{H-C}(3')$, 43 H of chol, 9 CH_2 , 4 $\text{H-C}(3)$ of DBU, 4 $\text{H-C}(4)$ of DBU).

3'-Deoxyadenylyl-(2' → 5')-3'-deoxyadenylyl-(2' → 5')-3'-O-{2-[2-(cholest-5-en-3 β -yloxycarbonyloxy)ethoxy]ethyl}adenosine Bis(1,8-diazobicyclo[5.4.0]undec-7-enium) Salt (**60**). As described for **59**, with **57** (470 mg, 170 μmol) in $\text{MeOH}/\text{CHCl}_3$ 4:1 (5 ml) containing 2% of TsOH. After workup, the residue was treated with 0.5M DBU/MeCN (10 ml), the soln. at r.t. for 3 d, then neutralized with 1M AcOH, and evaporated, and the residue washed and centrifugated several times with MeCN: 220 mg (80%) of **60**. Colourless powder. TLC ($\text{CH}_2\text{Cl}_2/\text{H}_2\text{O}/\text{MeOH}$ 50:20:4): R_f 0.35. HPLC (0.1M (Et_3NH)OAc buffer (pH 7)/THF/MeCN 15:10:75) (HPLC see **53** for A–C; gradient: 0–20 min 90% A in B → 100% B, 20–40 min 100% B → 100% C): t_R 36.80 min.

3'-Deoxyadenylyl-(2' → 5')-3'-deoxyadenylyl-(2' → 5')-3'-O-[5-(cholest-5-en-3 β -yloxycarbonyl)pentyl]-adenosine Bis(1,8-diazobicyclo[5.4.0]undec-7-enium) Salt (**61**). a) A soln. of **58** (16 mg, 5.8 μmol) in $\text{MeOH}/\text{CHCl}_3$ 4:1 (1 ml) containing 2% of TsOH was stirred at r.t. for 20 min. The mixture was diluted with CH_2Cl_2 (20 ml) and washed with sat. NaHCO_3 soln. (3 \times 20 ml) and the aq. phase re-extracted with CH_2Cl_2 (3 \times 20 ml). The org. layer was dried (Na_2SO_4) and evaporated and the residue dissolved in CH_2Cl_2 and treated with Et_2O . A colourless powder was obtained on centrifugation. After co-evaporation with dry pyridine (3 \times 5 ml), this solid was dissolved in 0.5M DBU/MeCN (0.35 ml) and the soln. stirred at r.t. for 3 d, then neutralized with 1M AcOH, evaporated, and co-evaporated with toluene (3 \times 5 ml). The residue was washed and centrifugated several times with MeCN: 6.0 mg (67%) of **61**. Colourless powder. TLC ($\text{CH}_2\text{Cl}_2/\text{H}_2\text{O}/\text{MeOH}$ 50:20:4): R_f 0.31. HPLC (0.1M (Et_3NH)OAc buffer (pH 7)/THF/MeCN 15:10:75): t_R 3.60 min.

b) As described before, with **66** (14 mg, 5.1 μmol) in $\text{MeOH}/\text{CHCl}_3$ 4:1 (1 ml) containing 2% of TsOH. After workup, the residue was treated with 0.5M DBU/MeCN (0.33 ml), the soln. at r.t. for 3 d, then neutralized with 1M AcOH; and evaporated, and the residue washed and centrifugated several times with MeCN: 4.6 mg (53%) of **61**. Colourless powder.

3'-O-(5-Carboxypentyl)-5'-O-[(4-methoxyphenyl)diphenylmethyl]-N⁶-[2-(4-nitrophenyl)ethoxycarbonyl]-adenosine (**62**). A soln. of **31** (81 mg, 88 μ mol) in 0.1M DBU/MeCN (4.5) was stirred at r.t. for 3 h, then neutralized with 1M AcOH, and evaporated. The residue was dissolved in CHCl₃ (20 ml) and the soln. washed with H₂O (3 \times 20 ml). The aq. phase was re-extracted with CHCl₃ (3 \times 20 ml), the combined org. layer dried (Na₂SO₄), and evaporated, and the residue purified by FC (silica gel (5 g), 1.5 \times 9 cm; CH₂Cl₂ (100 ml), CH₂Cl₂/MeOH 95:5 (100 ml)); 54 mg (72%) of **62**. Colourless foam. TLC (CHCl₃/MeOH 9:1): *R*_f 0.38. UV (MeOH): 266(4.48), 232(4.35). ¹H-NMR ((D₆)DMSO): 12.01 (br. s, COOH); 10.63 (s, NH); 8.58, 8.55 (2s, H-C(2), H-C(8)); 8.15 (d, 2 H *o* to NO₂); 7.60 (d, 2 H *m* to NO₂); 7.34–7.17 (m, 12 H of MeOTr); 6.83 (d, 2 H *o* to MeO); 5.99 (d, *J* = 4.4, H-C(1')); 5.98 (d, OH-C(2')); 4.91 (dd, H-C(2')); 4.37 (t, CH₂CH₂O of npeoc); 4.20–4.08 (m, H-C(4'), H-C(3')); 3.71 (s, MeO); 3.65–3.18 (m, CH₂O-C(3'), 2 H-C(5')); 3.09 (t, CH₂CH₂O of npeoc); 2.16 (t, CH₂COO); 1.68–1.20 (m, 3 CH₂). Anal. calc. for C₄₅H₄₆N₆O₁₁ (846.9): C 63.82, H 5.47, N 9.92; found: C 63.35, H 5.72, N 9.58.

3'-O-(5-Carboxypentyl)-5'-O-[(4-methoxyphenyl)diphenylmethyl]-N⁶-[2-(4-nitrophenyl)ethoxycarbonyl]-2'-O-[2-(4-nitrophenyl)ethoxysulfonyl]adenosine (**63**). To **62** (56 mg, 66 μ mol), which was co-evaporated in abs. pyridine (2 \times 5 ml), 2-(4-nitrophenyl)ethoxysulfonyl chloride [25] (40 mg, 0.16 mmol) and dry pyridine (5 ml) were added. The mixture was kept at r.t. for 4 h and then evaporated and co-evaporated with toluene (3 \times 10 ml). The residue was dissolved in CHCl₃ (10 ml), the soln. washed with sat. NaCl soln. (3 \times 20 ml), and the aq. phase re-extracted with CHCl₃ (3 \times 20 ml). The org. layer was dried (Na₂SO₄) and evaporated and the residue purified by FC (silica gel (5 g), 1.5 \times 8 cm; CH₂Cl₂ (50 ml), CH₂Cl₂/MeOH 99:1 (50 ml), 98:2 (50 ml)); 60 mg (86%) of **63**. Colourless foam. TLC (CHCl₃/MeOH 9:1): *R*_f 0.69. UV (CH₂Cl₂): 266(4.59), 237(4.39). ¹H-NMR ((D₆)DMSO): 11.97 (br. s, COOH); 10.66 (s, NH); 8.60, 8.50 (2s, H-C(2), H-C(8)); 8.18–8.11 (m, 4 H *o* to NO₂); 7.61–7.46 (m, 4 H *m* to NO₂); 7.32–7.13 (m, 12 H of MeOTr); 6.81 (d, 2 H *o* to MeO); 6.38 (d, *J* = 3.1, H-C(1')); 6.02 (dd, H-C(2')); 4.71 (t, H-C(3')); 4.38 (t, CH₂CH₂O of npeoc); 4.14 (m, H-C(4')); 3.92–3.84 (m, CH₂CH₂O of npes); 3.71 (s, MeO); 3.63–3.15 (m, CH₂O-C(3'), 2 H-C(5')); 3.15–3.08 (m, CH₂CH₂O of npeoc, CH₂CH₂O of npes); 2.11 (t, CH₂COO); 1.50–1.16 (m, 3 CH₂). Anal. calc. for C₅₃H₅₃N₇O₁₅S (1060.1): C 60.05, H 5.04, N 9.25; found: 60.02, H 5.30, N 8.53.

3'-O-[5-(Cholest-5-en-3 β -yloxycarbonyl)pentyl]-5'-O-[(4-methoxyphenyl)diphenylmethyl]-N⁶-[2-(4-nitrophenyl)ethoxycarbonyl]-2'-O-[2-(4-nitrophenyl)ethoxysulfonyl]adenosine (**64**). As described for **15**, with **63** (31 mg, 29 μ mol), EDC \cdot HCl (17 mg, 89 μ mol), DMAP (12 mg, 98 μ mol), abs. CH₂Cl₂ (2 ml), and cholesterol (34 mg, 88 μ mol). Workup and purification by FC (silica gel (5 g), 1.5 \times 8 cm; toluene (25 ml), toluene/AcOEt 9:1 (25 ml), 7:1 (40 ml), 5:1 (30 ml), 1:1 (40 ml)) led to 24 mg (60%) of **64**. Colourless foam. TLC (toluene/AcOEt 1:1): *R*_f 0.50. UV (CH₂Cl₂): 266(4.57), 237(4.41). ¹H-NMR ((D₆)DMSO): 10.69 (s, NH); 8.61, 8.52 (2s, H-C(2), H-C(8)); 8.15–8.10 (m, 4 H *o* to NO₂); 7.60–7.46 (m, 4 H *m* to NO₂); 7.30–7.13 (m, 12 H of MeOTr); 6.82 (d, 2 H *o* to MeO); 6.38 (d, *J* = 3.1, H-C(1')); 6.00 (dd, H-C(2')); 5.29 (m, H-C(6) of chol); 4.72 (m, H-C(3')); 4.39 (m, CH₂CH₂O of npeoc, H-C(3) of chol); 4.12 (m, H-C(4')); 3.85 (m, CH₂CH₂O of npes); 3.73 (s, MeO); 3.60–3.08 (m, CH₂O-C(3'), 2 H-C(5'), CH₂CH₂O of npeoc, CH₂CH₂O of npes); 2.22–0.63 (m, CH₂COO, 43 H of chol, 3 CH₂). Anal. calc. for C₈₀H₉₇N₇O₁₅S (1428.8): C 67.25, H 6.84, N 6.86; found: C 67.62, H 7.40, N 5.83.

3'-O-[5-(Cholest-5-en-3 β -yloxycarbonyl)pentyl]-N⁶-[2-(4-nitrophenyl)ethoxycarbonyl]-2'-O-[2-(4-nitrophenyl)ethoxysulfonyl]adenosine (**65**). As described for **37**, with **64** (71 mg, 50 μ mol) in MeOH/CHCl₃ 4:1 (1 ml) containing 2% of TsOH. Workup and FC (silica gel (5 g), 1.5 \times 6 cm; CH₂Cl₂ (50 ml), CH₂Cl₂/MeOH 99:1 (50 ml), 98:2 (50 ml)) gave 51 mg (89%) of **65**. Colourless foam. TLC (CH₂Cl₂/MeOH 95:5): *R*_f 0.51. UV (MeOH): 272 (sh, 4.51), 267 (4.55), 251 (sh, 4.45). ¹H-NMR ((D₆)DMSO): 10.66 (s, NH); 8.69, 8.56 (2s, H-C(2), H-C(8)); 8.16 (m, 4 H *o* to NO₂); 7.60–7.45 (m, 4 H *m* to NO₂); 6.34 (d, *J* = 4.3, H-C(1')); 5.73 (dd, H-C(2')); 5.31 (m, OH-C(5'), H-C(6) of chol); 4.40 (m, H-C(3'), CH₂CH₂O of npeoc, H-C(3) of chol); 4.11 (m, H-C(4')); 3.90–3.50 (m, CH₂O-C(3'), 2 H-C(5'), CH₂CH₂O of npes); 3.10 (m, CH₂CH₂O of npeoc, CH₂CH₂O of npes); 2.24–0.61 (m, CH₂COO, 43 H of chol, 3 CH₂). Anal. calc. for C₆₀H₈₁N₇O₁₄S (1153.4): C 62.32, H 7.06, N 8.48; found: C 61.97, H 7.50, N 7.87.

3'-Deoxy-5'-O-[(4-methoxyphenyl)diphenylmethyl]-N⁶-[2-(4-nitrophenyl)ethoxycarbonyl]adenyl-yl-{2'-[O^p-[2-(4-nitrophenyl)ethyl]} \rightarrow 5'}-3'-O-[5-(cholest-5-en-3 β -yloxycarbonyl)pentyl]-N⁶-[2-(4-nitrophenyl)ethoxycarbonyl]-2'-O-[2-(4-nitrophenyl)ethoxysulfonyl]adenosine (**66**). As described for **42**, with **65** (36 mg, 31 μ mol), **1** [15] (95 mg, 57 μ mol), 1*H*-tetrazole (11 mg, 0.16 mmol), and abs. MeCN (2 ml) mixed with abs. CH₂Cl₂ (1 ml). Workup and purification by FC (silica gel (5 g), 1.5 \times 10 cm; CH₂Cl₂ (50 ml), CH₂Cl₂/MeOH 99:1 (50 ml), 98:2 (50 ml)) yielded 42 mg (49%) of **66**. Colourless foam. TLC (CH₂Cl₂/MeOH 95:5): *R*_f 0.38. UV (CH₂Cl₂): 266(5.00). ¹H-NMR (CDCl₃): 8.62–8.48, 8.20–7.95 (2m, 3 H-C(2), 3 H-C(8), 12 H *o* to NO₂); 7.41–7.13 (m, 12 H *m* to NO₂, 12 H of MeOTr); 6.78 (d, 2 H *o* to MeO); 6.18–6.00 (m, 3 H-C(1')); 5.72–5.30 (m, 3 H-C(2'), H-C(6)

of chol); 4.60–4.15 (*m*, 2 $\text{CH}_2\text{CH}_2\text{O}$ of npe, H–C(3'), 3 H–C(4'), 3 $\text{CH}_2\text{CH}_2\text{O}$ of npeoc, 4 H–C(5'), H–C(3) of chol); 3.73 (*s*, MeO); 3.65–2.95 (*m*, $\text{CH}_2\text{CH}_2\text{O}$ of npes, CH_2O –C(3'), 2 H–C(5'), 2 $\text{CH}_2\text{CH}_2\text{O}$ of npe, 3 $\text{CH}_2\text{CH}_2\text{O}$ of npeoc, $\text{CH}_2\text{CH}_2\text{O}$ of npes); 2.48–0.65 (*m*, CH_2COO , 4 H–C(3'), 43 H of chol, 3 CH_3). Anal. calc. for $\text{C}_{134}\text{H}_{149}\text{N}_{21}\text{O}_{37}\text{P}_2\text{S}$ (2739.8): C 58.74, H 5.48, N 10.74; found: C 59.13, H 5.45, N 9.95.

REFERENCES

- [1] T. Wagner, W. Pfeleiderer, *Helv. Chim. Acta* **1997**, *80*, 200.
- [2] F. Barré-Sinoussi, J. C. Chermann, F. Rey, M. T. Nugeyre, S. Chamaret, J. Gruest, C. Daugey, C. Axler-Blin, F. Vézinet-Brun, C. Rouzioux, W. Rozenbaum, L. Montagnier, *Science* **1983**, *220*, 868.
- [3] M. Popovic, M. G. Sarngadharan, E. Read, R. C. Gallo, *Science* **1984**, *224*, 497.
- [4] C. Périgaud, G. Gosselin, J.-L. Imbach, *Nucleosides Nucleotides* **1992**, *11*, 903.
- [5] E. De Clercq, *J. Med. Chem.* **1995**, *38*, 2491.
- [6] P. F. Torrence, in 'Biological Response Modifiers. New Approaches to Disease Intervention', Ed. P. F. Torrence, Academic Press, Orlando, FL, 1985, pp. 77–105.
- [7] N. Fujii, in 'Progress in Molecular and Subcellular Biology', Eds. W. E. G. Müller, and H. C. Schröder, Springer Verlag, Berlin, 1994, Vol. 14, 150–175.
- [8] H. C. Schröder, M. Kleve, W. E. G. Müller, in 'Progress in Molecular and Subcellular Biology', Eds. W. E. G. Müller and H. C. Schröder, Springer Verlag, Berlin, 1994, Vol. 14, p. 176–197.
- [9] P. Doetsch, J. M. Wu, Y. Sawada, R. J. Suhadolnik, *Nature (London)* **1981**, *291*, 355.
- [10] R. Charubala, W. Pfeleiderer, *Tetrahedron Lett.* **1980**, *21*, 4077.
- [11] W. E. G. Müller, B. E. Weiler, R. Charubala, W. Pfeleiderer, L. Leserman, R. W. Sobol, R. J. Suhadolnik, H. C. Schröder, *Biochemistry* **1991**, *30*, 2027.
- [12] D. C. Montefiori, R. W. Sobol, Jr., S. W. Li, N. L. Reichenbach, R. J. Suhadolnik, R. Charubala, W. Pfeleiderer, A. Modlisewsky, W. E. Robinson, Jr., W. M. Mitchell, *Procl. Natl. Acad. Sci. U.S.A.* **1989**, *86*, 7191.
- [13] H. C. Schröder, R. J. Suhadolnik, W. Pfeleiderer, R. Charubala, *Int. J. Biochem.* **1992**, *24*, 55.
- [14] M. Wasner, E. E. Henderson, R. J. Suhadolnik, W. Pfeleiderer, *Helv. Chim. Acta* **1994**, *77*, 1757.
- [15] C. Hörndler, W. Pfeleiderer, *Helv. Chim. Acta* **1996**, *79*, 718.
- [16] F. Himmelsbach, B. S. Schulz, T. Trichtinger, R. Charubala, W. Pfeleiderer, *Tetrahedron* **1984**, *40*, 59.
- [17] W. Pfeleiderer, F. Himmelsbach, R. Charubala, H. Schirmeister, A. Beiter, B. Schulz, T. Trichtinger, *Nucleosides Nucleotides* **1985**, *4*, 81.
- [18] W. Pfeleiderer, M. Schwarz, H. Schirmeister, *Chem. Scr.* **1986**, *26*, 147.
- [19] J. F. M. de Roij, G. Wille-Hazeleger, P. H. van Deursen, J. Serdijn, H. J. van Boom, *Recl. Trav. Chim. Pays-Bas* **1979**, *98*, 537.
- [20] J. H. van Boom, P. M. J. Burgers, *Tetrahedron Lett.* **1979**, *52*, 4875.
- [21] H.-U. Blank, D. Frahn, A. Myles, W. Pfeleiderer, *Liebigs Ann. Chem.* **1970**, *742*, 34.
- [22] A. Myles, W. Pfeleiderer, *Chem. Ber.* **1973**, *105*, 3327.
- [23] K. W. Pankiewicz, J. Kreminski, L. A. Ciszewski, W.-Y. Ren, K. A. Watanabe, *J. Org. Chem.* **1992**, *57*, 553.
- [24] M. Pfister, W. Pfeleiderer, *Nucleosides Nucleotides* **1987**, *6*, 505.
- [25] M. Pfister, H. Schirmeister, M. Mohr, S. Farkas, K.-P. Stengele, T. Reiner, M. Dunkel, S. Gokhale, R. Charubala, W. Pfeleiderer, *Helv. Chim. Acta* **1995**, *78*, 1705.
- [26] M. Wasner, R. J. Suhadolnik, S. E. Horvath, M. E. Adelson, N. Kon, M.-X. Guan, E. E. Henderson, W. Pfeleiderer, *Helv. Chim. Acta* **1996**, *79*, 609.